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GENERAL INTRODUCTION
Cancer is a leading cause of death around the world. The World Health Organization 
estimates that without intervention 84 million people will die of cancer between 2005 
and 2015 [1]. For effective cancer therapy, it is necessary to improve our knowledge of 
cancer physiopathology, discover new anti-cancer drugs and develop novel biomedical 
technologies. Cancer therapy has become a multidisciplinary challenge requiring close 
collaboration among clinicians, biological researchers, material scientists, and biomedical 
engineers [2]. Cancer therapeutics aim to prevent tumor progression, improve the quality 
of life and expand the time of survival, with the ultimate goal to cure the patient. The 
potency of a cancer therapeutic is determined by its ability to eliminate cancerous tissue 
without damaging surrounding healthy tissue [3]. However, pharmacological agents are 
usually non-specifically distributed throughout the body and their efficacy is often limited 
due to severe side effects, indicating that tissue selectivity is a major problem. To overcome 
problems associated with conventional (chemo)-therapeutics and improve their pharma-
cological properties, antibody-drug conjugates have been developed. The first concept 
was already described in the early 20th century by Paul Ehrlich, while the first credible 
experiments were performed in 1958 [4,5]. Currently, only four antibody-drug conjugates 
have been approved by the FDA, of which the first antibody-drug conjugate (Rituximab) 
in oncology was approved in 1997 [4]. The antibody-drug conjugate concept combines a 
tumor-specific antibody with a cytotoxic drug to specifically target this drug to the tumor 
[6]. After binding, certain antibodies -not all- trigger internalization into the target cell 
together with the anti-tumor drug. Subsequently, the drug is released and the tumor cell 
eliminated. To increase the anti-tumor drug concentration, researchers pursued new drug 
delivery systems [7–10]. Drug delivery systems are carrier materials of which polymer-drug 
conjugates were first described in 1955 by Jatzkewitz that led to the discovery of multiple 
drug delivery systems in the following years [11]. In 1990, the first polymer-drug conjugate 
(Adagen) was approved by the FDA [12] and in 1995, the first liposomal formulations were 
approved by the FDA (Doxil and Abelcet) [13]. Drug delivery systems are able to transport 
higher quantities of anti-tumor drug molecules. By delivering pharmacologically high 
concentrations of active agents more selectively to pathological sites, drug delivery 
systems aim to improve the balance between efficacy and toxicity of systemically 
administered therapeutics. To design a novel drug delivery system that can efficiently 
deliver anti-tumor therapeutics to the targeted site via intravenous injection, various 
specifications need to prevail, as summarized in Table 1. Currently, a variety of drug delivery 
systems has been designed and characterized including liposomes [14–16], polymer-based 
drug delivery systems [17–19], and protein-based drug delivery systems [20–22]. 
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TUMOR MICROENVIRONMENT
The tumor microenvironment differs considerably from normal tissue, with regard to vascular 
structure, oxygenation, perfusion, pH, and metabolic state. To probe the possibility to 
utilize drug delivery systems for cancer therapy, researchers can employ different therapeutic 
strategies based on these differences. Here, differences in terms of tumor vasculature will 
be described, as they are most relevant for the design of tumor targeted drug delivery 
systems.
Angiogenesis
Angiogenesis is the physiological process involved in the formation of new blood vessels 
from pre-existing vessels and is a vital process in the development of a solid tumor. Once 
a tumor size has reached a diameter of 1 – 2 mm3, simple diffusion of oxygen and nutrients 
from the microvasculature becomes insufficient [23]. Tumors larger than 2 mm3 require 
angiogenesis to generate their own blood supply. Angiogenesis can be divided into five 
stages: 1. endothelial cell activation, 2. basement membrane degradation, 3. endothelial 
cell activation, 4. vessel formation, and 5. angiogenic remodeling. All these stages are 
regulated by a fine balance of activators, such as the growth factors vascular endothelial 
growth factor (VEGF) and platelet derived growth factor (PDGF), and inhibitors, like the 
statins angiostatin and endostatin [24,25]. Immature vasculature structures undergo 
extensive remodeling during which the vessels are stabilized by pericytes and smooth 
muscle cells. In tumors, often aberrant and immature vascular structures are present with 
altered endothelial cell-pericyte ratios, resulting in irregularly shaped and leaky tumor blood 
Table 1  Goals and specifications of drug delivery systems [2]
1. Increase drug concentrations in the tumor through:
 (a) passive targeting
 (b) active targeting
2. Decrease drug concentration in healthy tissue
3. Improve pharmacokinetic and pharmacodynamic profiles
4. Improve drug solubility to allow intravenous administration
5. Release a minimum of drug during transit
6. Release a maximum of drug at the target site
7. Increase drug stability and reduce drug degradation
8. Improve internalization and intracellular delivery
9. Improve biocompatibility and biodegradability
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vessels [26]. The ability of tumors to progress from a non-angiogenic to an angiogenic 
phenotype, also called the “angiogenic switch”, is central to progression of cancer and 
allows the spreading of cancer cells throughout the body, leading to metastasis [27].
Enhanced Permeability and Retention effect
Structural changes in vascular pathophysiology could provide opportunities for the use of 
drug delivery systems, in particular nano-sized particles. Before such nanoparticles reach 
the target site, they need to travel through the vascular bed. For cancer, an effective 
strategy is based on the enhanced permeability effect (EPR) associated with hyperperme-
ability of tumor vasculature and lack of lymphatic drainage (Fig. 1) [28–30]. Nanoparticles 
entered into the tumor are not efficiently removed and thus retained in the tumor. 
Nanoparticles do not extravasate through normal endothelium since tight endothelial 
Figure 1  Passive and active targeting approaches of nanocarriers in cancer. Passive tumor 
targeting is achieved by extravasation of nanocarriers through increased permeability of the tumor 
vasculature and ineffective lymphatic drainage (EPR effect). Cell penetrating peptides (left inset) can 
be used in passive targeting devices to facilitate intracellular uptake of nanocarriers. Active tumor 
targeting (right inset) can be achieved by functionalization of nanocarriers with targeting ligands 
that promote cell specific recognition and binding to tumor cells. Antibodies and CPPs may also be 
combined. Figure was adapted from Park [35].
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junctions (5 – 10 nm) between endothelial cells prevent extravasations of small particles 
[31]. However, the cut-off size for permeability in individual tumors varies between 200 – 
800 nm [32]. Therefore, particle size has a fundamental effect on biodistribution [33]. 
Due to this EPR effect, drug delivery systems (<800 nm) can extravasate from the blood 
vessels to the tumor and accumulate, thereby creating high local drug concentrations [34]. 
PRINCIPLES OF DRUG TARGETING TO TUMORS
Drug delivery refers to administration of an active pharmaceutical compound to achieve 
an increased drug accumulation at the tumor site compared to other tissues and organs. 
Current chemotherapy still fails in many cases because the drug concentration at the 
tumor site is too low and the drug is usually distributed nonspecifically throughout the 
body, thereby affecting healthy tissue as well. In this section, we will concentrate on 
nanoparticulate drug targeting systems to tumors based on the EPR effect (passive 
targeting), on the use of targeting moieties (active targeting), and enhanced intracellular 
delivery by cell penetrating peptides (Fig. 2).
Passive targeting
The passive targeting concept utilizes the transport of nanocarriers through (leaky) tumor 
capillary fenestrations into the tumor interstitium, facilitated by long systemic circulation 
times, as nanocarriers are more likely to reach the tumor site through the EPR effect 
when circulating for a longer period of time in the circulation (Fig. 1). This is accompanied 
with changes in the tumor microenvironment, as described in section ‘tumor micro-
environment’. The concept of the EPR effect was first described by Matsumura and Maeda 
by using one of the first protein-polymer conjugates (smancs) [29]. The enhanced 
drug-carrier system effect was achieved due to decreased systemic drug elimination 
through renal excretion, prolonged circulation, low tumor lymphatic drainage, and tumor 
hyperpermeability, currently known as the passive targeting phenomenon. Due to these 
features, drug delivery systems can reach levels 10 to 100 times higher in tumor tissue in 
comparison with classical chemotherapeutics [35].
Passive targeting approaches using nanoparticles have been largely used in clinical 
setting as the treatment results in fewer side effects compared to classical chemo-
therapeutics. However, delivery of the ‘nanomedicine’ to the interstitial fluid through the 
EPR effect does not guarantee intracellular delivery of the therapeutic drug. For optimal 
drug delivery to tumors, drug carriers must deliver their payload into the tumor cells [36]. 
Due to the non-specific process of passive targeting, drug carriers deliver their payload 
not only to (tumor) cells, but also in the interstitial fluid in the vicinity of tumor tissue. The 
consequence of drug release in the interstitium can result in multidrug resistance [37,38], 
because anti-tumor drug concentrations are too low which allows resistant tumor cells to 
13
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remove the drug by an efflux pump [39]. To overcome these limitations and to achieve 
enhanced drug delivery, the active targeting approach is being developed.
Active targeting
The opposite of passive targeting, ‘active targeting’, relies on the use of components such 
as antibodies and peptides with specific binding affinities for tumor targets such as 
receptors, and that are bound to the drug carrier systems. This approach also takes 
advantage of the EPR effect for accumulation of the drug carrier system into the interstitial 
fluid of the tumor. However, a certain class of ligands can facilitate the entry of nanoparticles 
to tumor cells via receptor-mediated endocytosis, after which they can release their drug 
payload to provide a therapeutic effect [40]. Examples of potential targets for actively 
targeted nanomedicine formulation to tumor cells are folate [41,42], transferrin [43,44], and 
mucin-1 [45,46].
Figure 2  Current approaches in drug delivery can be divided into passive, active, and intracellular 
targeting mechanisms. To employ passive targeting, the tumor microenvironment and enhanced 
permeability (EPR) effect are important parameters for nanoparticles to extravagate to the tumor 
site. In order to actively target tumor cells, this can be performed by targeted nanocarriers (antibody 
targeting), receptor targeting or by using immunoconjugates. To enhance intracellular drug delivery 
cell penetrating peptides can be employed.
14
CHAPTER 1
Enhanced intracellular uptake by cell penetrating peptides
The inability of therapeutics to reach their designated intracellular target site is one of the 
main obstacles for administering active molecules, particularly where cell membranes 
prevent nanoparticulate drug delivery systems from entering the cell in the absence of 
active transport [47]. In order to overcome these limitations, cell penetrating peptides 
(CPPs) have been used for intracellular delivery of a broad variety of cargos including 
multiple nanoparticulate drug delivery systems [48]. Amongst all CPPs, transactivator of 
transcription (TAT) peptide has been the most widely exploited CPP for the intracellular 
delivery of different sized cargoes and/or drug delivery systems [49]. 
Although of considerable potential, CPPs also have some limitations. CPPs have the 
undesirable characteristic of non-specificity and can enter any cell they come into contact 
with [50]. This lack of selectivity can induce toxic effects in normal tissues. In addition, 
the stability of the peptide in biological systems is not optimal, since peptides can be 
enzymatically cleaved by plasma enzymes [51,52]. In order to prevent cleavage of the 
peptide, a protease-resistance D-form of the peptide is developed, instead of the naturally 
occurring L-amino acid form, that cannot be degraded by these enzymes [53]. This 
approach could overcome the cleavage of the peptide during circulation, however, 
non-specificity is still an obstacle. To overcome the non-specificity problem, CPPs may be 
incorporated in so called ‘smart’ drug delivery systems [54]. These comprise  nanocarriers 
were CPPs are shielded by a polymer or antibody until arrival at the target site. The targeted 
antibodies provide specificity and via a stimulus-sensitive bond, protective moieties will 
be detached due to local environmental conditions (e.g. pH change) in order to achieve 
cellular uptake by the active CPP [47].
NANOPARTICLE PLATFORMS
Over the past three decades, considerable research efforts were put in the development 
of drug delivery systems using nanoparticles. Nanomedical approaches to drug delivery 
involve the development of nanoscale particles or macromolecules to improve the 
biological activity and pharmacokinetic profile of various drugs [55]. In recent years, a 
large variety of drug delivery systems have been developed. These classes of nanoparticles 
are discussed in more detail with the emphasis on protein-based nanoparticles.
Liposomes
Liposomes were first described in 1965 and are one of the first nanoparticle platforms to 
be applied in medicine [56]. Liposomes are spherical vesicles with an aqueous core and a 
single or multiple bilayered membrane structure composed of natural or synthetic lipids 
[14]. Lipids are characterized by their hydrophilic head and hydrophobic tail (Fig. 3). 
Depending on their design, they can range in size from tens of nanometers to several 
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micrometers [57]. For biomedical applications, liposomes have proven to be biocompatible, 
biodegradable, show low toxicity, can be manipulated with regard to liposomal size and 
can be modified to alter surface characteristics [58–60]. Liposomes are quickly removed 
from the circulation after administration. To improve the circulation half-life, liposomes 
need to be coated with polymers such as polyethylene glycol (PEG) to avoid recognition 
as foreign bodies by the immune system [61,62]. Furthermore, a wide range of therapeutics 
can be encapsulated in their internal aqueous compartment or embedded within the 
phospholipid bilayer. Currently, some liposomal formulations are in clinical use. Examples 
are Doxil, Caelyx, and Myocet, all nanometer-sized liposomes with encapsulated doxorubicin 
which are used to treat Kaposi’s sarcoma, ovarian cancer, breast cancer and multiple 
myeloma [63–65]. However, the limited chemical and physical stability of liposomes 
during manufacturing and storage still poses a challenge [66].
Polymer-based nanoparticles
Polymeric nanoparticles can be produced from both natural and synthetic polymers. The 
most widely used polymers for nanoparticles are polylactic acid (PLA), polyglycolic acid 
(PGA), poly(lactide-co-glycolic) acid copolymer (PLGA), and [N-(2-hydroxypropyl)-methac-
rylamide copolymer (HPMA) [68,69]. For polymer-based nanoparticles for drug delivery, 
size generally ranges between 10 – 400 nm [70]. However, depending on the methodology, 
polymeric particles can be prepared up to hundreds of micrometers. Besides the variety 
in polymers, many different compositions of polymer-based nanoparticles are developed, 
including polymersomes, polymeric nanoparticles, dendrimers, polymeric micelles, and 
Figure 3  Schematic representation of a liposome formed by phospholipids in an aqueous solution. 
Figure was adapted from Izon [67]
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polymer-drug conjugates (Fig. 4) [71]. Depending on their amphiphilicity, polymer-based 
nanoparticles can encapsulate hydrophilic or hydrophobic drug molecules and 
macromolecules such as proteins and nucleic acids [72,73]. Polymeric nanoparticles can 
be easily manipulated, without the loss of their physical, chemical, and biological 
properties. 
This characteristic can be exploited to enhance the function of the nanoparticles in cancer 
therapy. For instance, attachment of tumor-specific targeting moieties and PEGylation is 
needed to improve residence time in the blood and reduce nonspecific distribution, 
transforming them into so called ‘stealth’ nanoparticles [74–76]. A well-known issue with 
biodegradable polymers is uncertainty with regard to the safety, as they may give harmful 
degradation products [21]. Because degradation often results in a range of fragment sizes, 
toxicity is challenging to determine experimentally. Currently, many polymer- based 
nanoparticles for drug delivery are under development and several are being evaluated in 
clinical trials [18,71]. Among these, Genexol-PM, (polymeric micelle with paclitaxel) is 
already approved for use in metastatic breast cancer patients in South Korea.
Figure 4  Polymeric nanoparticles platform. Schematic representation of different types of polymeric 
nanoparticles for drug delivery. Polymeric nanoparticles consist more or less of similar core materials. 
They can be used in different settings to prepared variety of nanoparticles, such as polymersomes, 
polymeric nanoparticles or nanoshells, dendrimers, polymeric micelles, and polymer-drug conjugates. 
Figure was adapted from Alexis et al. [71].
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Protein-based drug delivery systems
In recent years, more research has focused on protein-based drug delivery systems due to 
their bioavailability, biocompatibility, and biodegradability coupled with low toxicity of 
their degradation products [77]. A variety of proteins has been used and characterized for 
drug delivery, such as albumin, gelatin, collagen, elastin, and casein [20]. Proteins are a 
class of natural molecules that have unique functionalities and potential applications in 
both biological as well as material fields and there are many different sizes and types of 
protein-based drug delivery systems, such as nanoparticles, microparticles, hydrogels, 
and films. Here, we will focus on the preparation of albumin-based nanoparticles.
Albumin nanoparticles
Albumin is a versatile protein carrier for drug delivery and an interesting material, because 
of its biodegradability, biocompatibility and its lack of toxicity [78]. Therefore, it is an ideal 
molecule to fabricate nanoparticles for drug delivery. Albumin-based nanoparticles are 
well tolerated by the body, as indicated by clinical studies with FDA approved albumin 
nano/micro particle formulations such as Albunex [79,80] and Abraxane [81,82]. Moreover, 
albumin drug delivery systems offer possibilities for surface modification due to the 
natural occurrence of functional groups (i.e. carboxylic and amine groups) enabling 
specific drug targeting to the site of action [83]. Albumin-based systems are considered 
safe since they are metabolizable in vivo by digestive enzymes into innocuous peptides 
[21]. In addition, albumin is thought to facilitate endothelial transcytosis of unbound and 
albumin-bound plasma constituents into the extravascular space. This process is initiated 
by binding of albumin to a cell surface, 60 kDa glycoprotein (gp60) receptor, to extravagate 
from the circulation as demonstrated for Abraxane [84].
Albumin-based lyophilisomes
Lyophilisomes are a novel class of proteinaceous biodegradable nano/micro drug delivery 
capsules prepared by freezing, annealing and Iyophilization [85]. This methodology results 
in globular structures ranging in the nano- and micro size range. The proposed mechanism 
of capsule formation comprises a three step procedure (freezing – annealing – lyophilization). 
Fast-freezing of biomolecules in solution (Fig. 5, step 1) results in phase separation 
between water (the main solvent) and biomolecule, which become organized into sheets 
(Fig. 5, step 2). Annealing (heating the preparation, but keeping the mixture under 0° C) 
rearranges the sheets into spheres and  lyophilization transforms spheres into capsules, 
most likely through  a 3D analogy of the coffee-stain mechanism (Fig. 5, step 3).
The system is highly flexible, allowing the incorporation of virtually any biomolecule in the 
wall and/or lumen. For instance, enzymes incorporated in the capsule wall and the lumen 
still exerted their biological activity, partly due to mild preparation conditions applied [85]. 
Lyophilisomes made of albumin may show potential as a carrier system to be used as a 
delivery system for anti-tumor drugs.
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AIMS AND OUTLINE OF THESIS
Nanotechnology is a field of research at the crossroads of biology, chemistry, physics, 
engineering, and medicine. Design of multifunctional nanoparticles capable of targeting 
cancer cells, and delivering and releasing drugs in a regulated manner are the future 
application of nanotechnology to oncological diseases. The aim of the research described 
in this thesis is to prepare and functionalize lyophilisomes made from albumin in order to 
obtain albumin-based nanoparticles that can act as a drug delivery system and eliminate 
ovarian tumor cells. In chapter 1, an overview of the most commonly used drug delivery 
systems is given and different strategies to target tumors more efficiently are discussed. 
Chapter 2 demonstrates that lyophilisomes show potential to act as a drug delivery 
system, as they were internalized by tumor cells and doxorubicin and curcumin loaded 
lyophilisomes were able to eliminated ovarian tumor cells in vitro. In addition, an adjusted 
lyophilisome methodology is described that results in a more monodisperse particle 
Figure 5  Cartoon of the proposed lyophilisome capsule formation. Capsule formation comprises 
a three-step procedure (freezing–annealing–lyophilization). Fast-freezing of biomolecules in 
solution (left upper panel) results in phase separation between water (the main solvent) and 
biomolecules, which become organized into sheets (right upper panel). Annealing rearranges the 
sheets into spheres and lyophilization transforms spheres into capsules, most likely due to a 3D 
analogy of the coffee-stain mechanism. Figure was adapted from Daamen et al. [85]. Copyright 
Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission.
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population. In chapter 3, lyophilisomes were modified with hKC4-antibodies against 
mucin-1 (MUC1) and shown to specifically target ovarian tumor cells overexpressing MUC1 
antigen. In Chapter 4, lyophilisomes were modified with cell penetrating peptides to 
facilitate their cellular uptake, which may result in a more efficient therapeutic outcome. 
Moreover, an additional technique (fluorescent activated cell sorting) is described to 
select  lyophilisomes below 1,000 nm. Chapter 5 describes the biodistribution of albumin- 
based lyophilisomes intravenously injected in mice. In addition, a new methodology to 
size-select lyophilisomes more precisely and with a higher absolute yield is given. Chapter 6 
concludes this thesis with a summary and future prospective.
20
CHAPTER 1
REFERENCES
 1.  World Health Organization (2007) Cancer Control: Knowledge into Action. WHO Guide for Effective Programmes. 
Palliative Care. 
 2.  Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: Passive and active tumor targeting 
of nanocarriers for anti-cancer drug delivery. J Control Release 148: 135-146.
 3.  Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer 
therapeutics. Adv Drug Deliv Rev 60: 1615-1626.
 4.  Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, et al. (2013) Linked-in: design and efficacy of antibody drug 
conjugates in oncology. Oncotarget 4: 397-412.
 5.  Mathe G, Tran Ba LO, Bernard J (1958) Effect on mouse leukemia 1210 of a combination by diazo-reaction of 
amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts. C R Hebd 
Seances Acad Sci 246: 1626-1628.
 6.  Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14: 154-169.
 7.  De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 3: 
133-149.
 8.  Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin 
Cancer Res 14: 1310-1316.
 9.  Sanvicens N, Marco MP (2008) Multifunctional nanoparticles--properties and prospects for their use in human 
medicine. Trends Biotechnol 26: 425-433.
 10.  Fadeel B, Garcia-Bennett AE (2009) Better safe than sorry: Understanding the toxicological properties of 
inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 62: 362-374.
 11.  Petros RA, Desimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev 
Drug Discov 9: 615-627.
 12.  Felice B, Prabhakaran MP, Rodriguez AP, Ramakrishna S (2014) Drug delivery vehicles on a nano-engineering 
perspective. Mater Sci Eng C Mater Biol Appl 41: 178-195.
 13.  Zhang Y, Chan HF, Leong KW (2013) Advanced materials and processing for drug delivery: the past and the 
future. Adv Drug Deliv Rev 65: 104-120.
 14.  Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160.
 15.  Al-Jamal WT, Kostarelos K (2011) Liposomes: from a clinically established drug delivery system to a nanoparticle 
platform for theranostic nanomedicine. Acc Chem Res 44: 1094-1104.
 16.  Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, et al. (2011) Ferri-liposomes as an MRI-visible drug-delivery 
system for targeting tumours and their microenvironment. Nat Nanotechnol 6: 594-602.
 17.  Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385: 113-142.
 18.  Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688-701.
 19.  Vaidya A, Agarwal A, Jain A, Agrawal RK, Jain SK (2011) Bioconjugation of polymers: a novel platform for 
targeted drug delivery. Curr Pharm Des 17: 1108-1125.
 20.  Maham A, Tang Z, Wu H, Wang J, Lin Y (2009) Protein-based nanomedicine platforms for drug delivery. Small 
5: 1706-1721.
 21.  Elzoghby AO, Samy WM, Elgindy NA (2012) Protein-based nanocarriers as promising drug and gene delivery 
systems. J Control Release 161: 38-49.
 22.  Neumann E, Frei E, Funk D, Becker MD, Schrenk HH, et al. (2010) Native albumin for targeted drug delivery. 
Expert Opin Drug Deliv 7: 915-925.
 23.  Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
 24.  Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
 25.  Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395.
 26.  Stollman TH, Ruers TJ, Oyen WJ, Boerman OC (2009) New targeted probes for radioimaging of angiogenesis. 
Methods 48: 188-192.
 27.  Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19: 329-337.
 28.  Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63: 131-135.
21
GENERAL INTRODUCTION
1
29.  Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: 
mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 
6387-6392.
 30.  Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in 
macromolecular therapeutics: a review. J Control Release 65: 271-284.
 31.  Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A (2005) Liposomal encapsulated anti-cancer drugs. 
Anticancer Drugs 16: 691-707.
 32.  Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: the need for precision in 
reporting particle size parameters. Eur J Pharm Biopharm 69: 1-9.
 33.  Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, et al. (2010) Size and shape effects in the biodistribution of 
intravascularly injected particles. J Control Release 141: 320-327.
 34.  Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp 
Pharmacol 3-53.
 35.  Park K (2012) Polysacharide-based near-infrared fluorescence nanoprobes for cancer diagnosis. Quant 
Imaging Med Surg 2: 106-113.
 36.  Tang J, Zhang L, Liu Y, Zhang Q, Qin Y, et al. (2013) Synergistic targeted delivery of payload into tumor cells by 
dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT. Int J Pharm 454: 31-40.
 37.  Gottesman MM (1993) How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal 
Foundation Award Lecture. Cancer Res 53: 747-754.
 38.  Simon SM, Schindler M (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad 
Sci U S A 91: 3497-3504.
 39.  Ullah MF (2008) Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian 
Pac J Cancer Prev 9: 1-6.
 40.  Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, et al. (2006) Antibody targeting of long-circulating 
lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. 
Cancer Res 66: 6732-6740.
 41.  Wang S, Low PS (1998) Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids 
to cancer cells. J Control Release 53: 39-48.
 42.  Wang X, Li J, Wang Y, Cho KJ, Kim G, et al. (2009) HFT-T, a targeting nanoparticle, enhances specific delivery of 
paclitaxel to folate receptor-positive tumors. ACS Nano 3: 3165-3174.
 43.  Qian ZM, Li H, Sun H, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis 
pathway. Pharmacol Rev 54: 561-587.
 44.  Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, et al. (2006) In vitro assessment of transferrin-conju-
gated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 29: 367-374.
 45.  Savla R, Taratula O, Garbuzenko O, Minko T (2011) Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin 
conjugate for imaging and treatment of cancer. J Control Release 153: 16-22.
 46.  Yu C, Hu Y, Duan J, Yuan W, Wang C, et al. (2011) Novel aptamer-nanoparticle bioconjugates enhances delivery 
of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 6: e24077.
 47.  Koren E, Torchilin VP (2012) Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 18: 
385-393.
 48.  Torchilin VP (2008) Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv 
Rev 60: 548-558.
 49.  Sawant R, Torchilin V (2010) Intracellular transduction using cell-penetrating peptides. Mol Biosyst 6: 628-640.
 50.  Martin I, texeidó M, Giralt E (2010) Building Cell Selectivity into CPP-Mediated Strategies. Pharmaceuticals 3: 
1456-1490.
 51.  Grunwald J, Rejtar T, Sawant R, Wang Z, Torchilin VP (2009) TAT peptide and its conjugates: proteolytic stability. 
Bioconjug Chem 20: 1531-1537.
 52.  Koren E, Apte A, Sawant RR, Grunwald J, Torchilin VP (2011) Cell-penetrating TAT peptide in drug delivery 
systems: proteolytic stability requirements. Drug Deliv 18: 377-384.
 53.  Verdurmen WP, Bovee-Geurts PH, Wadhwani P, Ulrich AS, Hallbrink M, et al. (2011) Preferential uptake of L- 
versus D-amino acid cell-penetrating peptides in a cell type-dependent manner. Chem Biol 18: 1000-1010.
22
CHAPTER 1
 54.  Torchilin V (2009) Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 71: 
431-444.
 55.  Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. 
Nat Rev Drug Discov 7: 771-782.
 56.  Bangham AD (1993) Liposomes: the Babraham connection. Chem Phys Lipids 64: 275-285.
 57.  Lelkes PI (1990) Liposomes: a practical approach. New RRC 49.
 58.  Torchilin VP (2006) Multifunctional nanocarriers. Adv Drug Deliv Rev 58: 1532-1555.
 59.  Gómez-Hens A, Fernández-Romero JM (2012) Analytical methods for the control of liposomal delivery 
systems. Trends in Analytical Chemistry 25: 167-178.
 60.  Bae SJ, Jung S, Um SH (2011) Budding dynamics of the lipid membrane. J Nanosci Nanotechnol 11: 6172-6176.
 61.  Romberg B, Hennink WE, Storm G (2008) Sheddable coatings for long-circulating nanoparticles. Pharm Res 25: 
55-71.
 62.  Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to 
practice. Pharmacol Rev 53: 283-318.
 63.  Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303: 1818-1822.
 64.  Duggan ST, Keating GM (2011) Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, 
ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma. Drugs 71: 2531-2558.
 65.  Slingerland M, Guchelaar HJ, Gelderblom H (2012) Liposomal drug formulations in cancer therapy: 15 years 
along the road. Drug Discov Today 17: 160-166.
 66.  Zhang JA, Pawelchak J (2000) Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC/
cholesterol liposomes under accelerated conditions. Part 1: Lipid hydrolysis. Eur J Pharm Biopharm 50: 357-364.
 67.  2014) Izon website. http://www.izon.com/media/webinars/.
 68.  Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid 
State Mater Sci 6: 319-327.
 69.  Tian H, Tang Z, Zhuang X, Chen X, Jing X (2011) Biodegradable synthetic polymers: Preparation, functionaliza-
tion and biomedical application. Prog Polym Sci 37: 237-280.
 70.  Rao JP, Geckeler EG (2011) Polymer nanoparticles: Preparation techniques and size-control parameters. Prog 
Polym Sci 36: 887-913.
 71.  Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of 
polymeric nanoparticles. Mol Pharm 5: 505-515.
 72.  Amjadi I, Rabiee M, Hosseini MS, Mozafari M (2012) Synthesis and Characterization of Doxorubicin-Loaded 
Poly(Lactide-co-glycolide) Nanoparticles as a Sustained-Release Anticancer Drug Delivery System. Appl 
Biochem Biotechnol 168: 1434-1447.
 73.  Park JH, Lee S, Kim JH, Park K, Kim K, et al. (2007) Ploymeric nanomdicine for cancer therapy. Prog Polym Sci 33: 
113-137.
 74.  Jokerst JV, Lobovkina T, Zare RN, Gambhir SS (2011) Nanoparticle PEGylation for imaging and therapy. 
Nanomedicine (Lond) 6: 715-728.
 75.  Cardoso MM, Peca IN, Roque AC (2012) Antibody-conjugated nanoparticles for therapeutic applications. Curr 
Med Chem 19: 3103-3127.
 76.  van Vlerken LE, Amiji MM (2006) Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. 
Expert Opin Drug Deliv 3: 205-216.
 77.  Jahanshahi M, Babaei Z (2008) Protein nanoparticle: A unique system as drug delivery vehicles. Afr J Biotechnol 
7: 4926-4934.
 78.  Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control 
Release 132: 171-183.
 79.  Feinstein SB, Cheirif J, Ten Cate FJ, Silverman PR, Heidenreich PA, et al. (1990) Safety and efficacy of a new 
transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol 16: 316-324.
 80.  Geny B, Mettauer B, Muan B, Bischoff P, Epailly E, et al. (1993) Safety and efficacy of a new transpulmonary echo 
contrast agent in echocardiographic studies in patients. J Am Coll Cardiol 22: 1193-1198.
 81.  Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, et al. (2002) Phase I and pharmacokinetic study of 
ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8: 
1038-1044.
23
GENERAL INTRODUCTION
1
 82.  Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, et al. (2005) Multicenter phase II trial of ABI-007, an 
albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23: 6019-6026.
 83.  Elzoghby AO, Samy WM, Elgindy NA (2011) Albumin-based nanoparticles as potential controlled release drug 
delivery systems. J Control Release 157: 168-182.
 84.  Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv 
Drug Deliv Rev 60: 876-885.
 85.  Daamen WF, Geutjes PJ, Nillesen STM, Van Moerkerk HTB, Wismans R, et al. (2007) Lyophilisomes: A new type 
of (bio)capsules. Adv Mater 19: 673-677.

Lyophilisomes as a new generation  
of drug delivery capsules
Etienne van Bracht, René Raavé, Wouter P.R. Verdurmen, 
Ronnie G. Wismans, Paul J. Geutjes, Roland E. Brock, 
Egbert Oosterwijk, Toin H. van Kuppevelt, Willeke F. Daamen
International Journal of Pharmaceutics, Volume 439, Issue 1-2, Page: 127-135, 2012
2
26
CHAPTER 2
ABSTRACT
Nanoparticulate drug delivery systems are currently explored to overcome critical 
challenges associated with classical administration forms. In this study, we present a drug 
delivery system based on a novel class of proteinaceous biodegradable nano/micro 
capsules, lyophilisomes. Lyophilisomes can be prepared from biomolecules without the 
need for amphiphilicity. Albumin-based lyophilisomes were prepared by freezing, 
annealing and lyophilizing, resulting in capsules ranging from 100 to 3,000 nm. 
Lyophilisomes were loaded with the anti-tumor drugs doxorubicin and curcumin using 
different concentrations and time/temperature regimes. Incubation in 0.1 mg/ml 
doxorubicin or 1.0 mg/ml curcumin resulted in an entrapment efficiency of 95±1% and 
4±1%, respectively. This corresponds to a drug loading of 0.24 mg doxorubicin per 
milligram albumin and 0.10 mg curcumin per milligram albumin. Drug release profiles 
from doxorubicin and curcumin-loaded lyophilisomes were studied in culture medium 
and showed slow release for doxorubicin (2.7% after 72 h), and rapid release for curcumin 
(55% after 72 h). When applied to cells, non-loaded lyophilisomes did not influence cell 
viability, even at high concentrations (1 mg/ml). Lyophilisomes were internalized by cells. 
When loaded with doxorubicin and curcumin, lyophilisomes strongly reduced cell 
proliferation and viability of SKOV-3 and HeLa cells, respectively, to a level similar or better 
compared to an equal amount of free drugs. In conclusion, albumin lyophilisomes show 
potential as (nano)carriers of drugs for tumor cell elimination.
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INTRODUCTION
The potency of a cancer therapeutic is determined by its ability to eliminate cancerous 
tissue without damaging surrounding healthy tissue. Anti-tumor drugs are usually 
distributed non-specifically throughout the body, thereby affecting healthy tissues as 
well. To generate a successful therapeutic device, it is essential to develop systems which 
increase drug concentrations in a site-specific manner [1]. Nano/micro carrier drug delivery 
systems including polymeric particles and liposomes protect the drug from the 
environment, and may prolong drug retention time, reduce clearance and minimize side 
effects [2–4]. For biomedical applications, it would be advantageous if capsules could be 
prepared from a wide repertoire of natural (proteinaceous) macromolecules, to address 
the variety of medical demands, such as site-specific delivery, receptor-mediated cellular 
uptake and physicochemical parameters such as pI and serum interaction.
Previously, our group described a new type of nano/micro biocapsule called “lyophilisome”, 
which can be prepared from a diversity of water-soluble macromolecules, including 
proteins, without the need for amphiphilicity [5]. The use of proteins for fabrication of 
drug delivery systems is well described in literature, which has resulted in a growing 
interest in protein delivery carriers as they are generally regarded as safe [6]. Using this 
methodology, the composition of the capsule wall can be modified and additional 
components can be incorporated into the wall (e.g. enzymes) with preserved biological 
activity, enabling an adaption to various applications [5]. In tumor targeting, albumin is an 
interesting material for carrier-mediated drug delivery, because of its bio degradability, 
biocompatibility, its lack of toxicity and of immunogenicity [7]. Lyophilisomes made of 
albumin may therefore show potential as a carrier system to be used as a delivery system for 
anti-tumor drugs such as doxorubicin and curcumin.
Doxorubicin is widely used in cancer chemotherapy and has a broad range of reactivity, 
showing anti-neoplastic activity against a number of human cancers [8,9]. The drug acts 
as an DNA intercalating agent that inhibits the enzyme topoisomerase II essential for DNA 
replication, resulting in cell death [10]. However, its clinical use is seriously hampered due to 
severe side effects [11–13]. 
Curcumin is used for its anti-tumor, anti-oxidant, and anti-inflammatory properties [14–18]. 
It affects cell proliferation, differentiation and apoptosis and the anti-carcinogenic properties 
are most likely due to effects on multiple molecular targets [19,20]. However, the water 
solubility of free curcumin is poor (maximally 11 ng/ml) [21]. It is therefore not possible to 
administer curcumin systemically.
In this study, we formulate a new protein-based drug delivery system consisting of 
lyophilisomes prepared from albumin using a freezing, annealing and lyophilization 
regime, followed by drug-loading. The loading and release characteristics of doxorubicin 
and curcumin are studied, and cytotoxicity and cellular uptake are evaluated. Finally, the 
tumor cell eliminating potential of drug-loaded lyophilisomes is described.
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MATERIALS & METHODS
Materials
Bovine serum albumin (BSA) was purchased from PAA Laboratories (Linz, Austria). 
Doxorubicin, curcumin, and fluorescein isothiocyanate (FITC) conjugated bovine albumin 
were purchased from Sigma Aldrich (Steinheim, Germany). Dylight 633 (amine reactive) 
was purchased from Pierce (Rockford, IL, USA). CellMask orange was purchased from 
Invitrogen (Breda, Netherlands). Glutaraldehyde and formaldehyde were obtained from 
Merck (Darmstadt, Germany). 
Methods
Preparation of lyophilisomes
A solution of 0.25% (w/v) BSA in 0.01 M acetic acid (20 µl droplets) was frozen in liquid 
nitrogen (-196°C). Generally, we use 40 ml corresponding to 100 mg albumin (2.5 mg/ml). 
In order to visualize the lyophilisomes, FITC-conjugated albumin was added to non-labeled 
albumin (1:10) in the starting solution prior to the preparation of lyophilisomes. The frozen 
albumin preparation was incubated at -10 to -20°C for 3 h (annealing step), and 
subsequently lyophilized [5]. This procedure results in hollow nano/micro spheres 
(“lyophilisomes”). The exact conditions of the freeze drying program are presented in 
more detail in Table S1 (Supplementary data). To stabilize the lyophilisomes, vapor 
crosslinking was performed using a 1:1 mixture of 25% glutaraldehyde and 37% 
formaldehyde for 2 h. To quench free aldehydes, 3.5 mg lyophilisomes were incubated in 
1 ml 1% (w/v) glycine (Scharlau, Barcelona, Spain) in phosphate buffered saline (PBS, pH 
7.4). Using gentle sonication (Branson Sonifier 250, 10 s, output 20) lyophilisomes were 
separated, washed three times in combination with three to four low-speed centrifugation 
steps (60x g; Thermo, Heraeus Fresco 17; Newport Pagnell, Great Britain) to remove large 
lyophilisomes and sheet-like structures, until no pellet was observed. After this procedure, 
about 30% of the original weight of lyophilisomes remained. One fifth of this preparation 
(200 µg) was used for loading experiments and taken up in 500 µl of drug solution (see 
section ‘Loading and visualization of doxorubicin and curcumin lyophilisomes’).
In order to produce red fluorescent lyophilisomes, Dylight 633 was activated by a 
N-hydroxysuccinimide ester and conjugated to the free amine groups in albumin 
(according to the manufacturer’s protocol), and subsequently dialyzed in 0.01 M acetic acid 
and mixed with non-labeled albumin in a 1:4 ratio, followed by lyophilisome preparation 
as earlier described.
Scanning electron microscopy
Lyophilisomes were deposited on poly-D-lysine coated cover slips or mounted on carbon 
tape, sputtered with gold, and analyzed using a JEOL JSM-6310 scanning electron 
microscope (Tokyo, Japan) at an accelerating voltage of 15 kV. 
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Transmission electron microscopy
Lyophilisomes were embedded in 1.5% (w/v) agarose, fixed in 2% (v/v) glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4), post-fixed with 1% (w/v) osmium tetroxide, dehydrated in 
an ascending series of ethanol, and embedded in Epon 812. Ultrathin sections (60 nm) 
were cut and picked up on Formvar-coated grids, post-stained with lead citrate and uranyl 
acetate, and examined in a JEOL 1010 transmission electron microscope (Tokyo, Japan).
Dynamic light scattering
Dynamic light scattering (DLS, Zetasizer Nano-S, Malvern Instruments Ltd., Malvern, UK) 
was used to measure particle size of lyophilisomes. Stabilized lyophilisomes were 
dispersed in 0.1% (v/v) Tween-20 (Sigma Aldrich, Steinheim, Germany) in PBS (PBS-T, pH 7.4) 
and analyzed by DLS.
Particle size measurements by qNano
The qNano was used to measure particle size of lyophilisomes [22]. Fluid cells were washed 
with de-izonized water and dried with a tissue. In the center of the lower fluid cell 80 µl 
standard electrolyte buffer, provided by manufacturer (Izon, Science Ltd., Burnside, New 
Zealand), was placed avoiding air bubbles. The membrane was mounted on the 
instrument. The upper fluid cell was placed into position and 50 µl of standard electrolyte 
buffer was added. Pore width was controlled by adjusting the arm of the tunable nanopore 
onto the holding stage, and voltage was controlled by the connected computer. To 
ensure a continuous flow of particles, a pore size of approximately 700 to 1,600 nm was 
used. At constant voltage (0.2 V), the pore was open when a direct correlation could be 
observed between ionic current and adjustment of the tunable arms of the nanopore. 
Finally, particles were added on the upper fluid cell for measurements. Data was analyzed 
with Izon Control Suite 2.1 software. 
Loading and visualization of doxorubicin and curcumin lyophilisomes
Lyophilisomes (200 µg) were incubated overnight in 500 µl 0.1 and 1.0 mg/ml doxorubicin 
in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4; 
Promega, Madison, WI, USA), and 0.1 and 1.0 mg/ml curcumin in 100% (v/v) ethanol at 
either 4°C, room temperature or 37°C. Subsequently, they were centrifuged (17,000x g), 
washed three times in 1.0 ml 0.1% PBS-T and stored at 4°C. Loaded capsules were deposited 
on poly-D-lysine coated cover slips and the location of doxorubicin and curcumin in 
lyophilisomes was studied using confocal laser scanning microscopy (Olympus FV1000, 
Olympus GmbH, Hamburg, Germany) and analyzed with FV 10-ASW 1.6 Viewer software. 
FITC-lyophilisomes and curcumin were visualized with an argon laser at 488 nm, Dylight 
633 lyophilisomes and doxorubicin with a diode laser at 559 and 635 nm, respectively.
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Entrapment efficiency
The entrapment efficiency of doxorubicin and curcumin in lyophilisomes was determined 
as follows: lyophilisomes were separated from the free drug using centrifugation (17,000x 
g) and washed three times in 1.0 ml PBS-T. The supernatant with free drug was collected 
and absorbance was measured spectrophotometrically using a Synergy 2 plate reader at 
490 nm for doxorubicin and 420 nm for curcumin (Biotek, Winooski, VT) assuming that 
drug not present in the supernatant was entrapped in lyophilisomes [23,24]. The 
concentration was calculated using a calibration curve of doxorubicin and curcumin in 
HEPES buffer and ethanol respectively and all measurements were performed in triplicate. 
Entrapment efficiency was calculated as follows: 
x 100
[Drug]total – [Drug]free
[Drug]total
Drug release from doxorubicin and curcumin loaded lyophilisomes 
Drug release from loaded lyophilisomes was examined at three temperatures (4°C, room 
temperature, and 37°C), at three time points (24, 48, and 72 h) and both in PBS and culture 
medium. Lyophilisomes (200 µg) were loaded with 500 µl of 0.1 mg/ml doxorubicin and 
1.0 mg/ml curcumin at room temperature as described above. Subsequently, samples 
were centrifuged (17,000x g, 5 min, 4°C) and washed three times in 1.0 ml PBS. Pellets were 
resuspended in 500 μl PBS or culture medium (RPMI 1640 + L-glutamine without phenol 
red, Gibco Karlsruhe, Germany). Culture medium was supplemented with 10% (v/v) 
heat-inactivated fetal calf serum (FCS; PAA Laboratories, Pasching, Austria). In this study, 
curcumin was dissolved in ethanol prior to loading. Released curcumin precipitated in the 
medium and was dissolved in ethanol and measured spectrophotometrically. Release was 
determined spectrophotometrically at 490 nm for doxorubicin and 420 nm for curcumin, 
and calculated as follows:
Release (%) = x 100
[Drug]released
[Drug]total
Cell culture
All culture media were purchased from Gibco (Karlsruhe, Germany) unless indicated 
otherwise. The human ovarian cancer cell line SKOV-3 was cultured in McCoy 5A GlutaMAX 
medium supplemented with 10% (w/v) FCS. HeLa cells were cultured in RPMI 1640 
GlutaMAX supplemented with 10% (w/v) FCS. The cells were cultured in a humidified 
atmosphere with 5% CO
2
 at 37°C. Subconfluent cells were dissociated with 0.05% (w/v) 
trypsin and 0.02% (w/v) ethylenediaminetetraacetic acid (EDTA) in Dulbecco’s-PBS (PAA 
Laboratories, Pasching, Austria) and were maintained as proliferating cultures.
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Cytotoxicity studies
To investigate the cell viability of cancer cells exposed to lyophilisomes with and without 
doxorubicin or curcumin, the 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-
benzene disulfonate (WST-1, Roche Diagnostics, Mannheim, Germany) cell proliferation 
assay was performed. SKOV-3 cells were chosen to analyze the cell eliminating potential of 
doxorubicin loaded lyophilisomes because this drug is frequently used to treat ovarian 
cancer [25,26]. HeLa cells were used to examine the effect of curcumin-loaded 
lyophilisomes, since this tumor cell line is susceptible to the cytotoxic effect of curcumin 
[23,27]. To access the efficiency of doxorubicin or curcumin on SKOV-3 and HeLa cells, free 
doxorubicin or curcumin was added to cells in an ascending concentration (0, 1, 5, 10, 20 
and 50 µM). To efficiently eliminate SKOV-3 and HeLa cells, 20 µM of free doxorubicin or 
curcumin was required. For curcumin, a stock solution (2 mM) was prepared in ethanol. 
This was further diluted in medium before adding to the cell culture. As a control, ethanol 
only was added in equal concentration to cells and this did not affect cell viability (results 
not shown). Cells were seeded into 96-well plates at a concentration of 2,000 cells per well. 
On the next day, equivalent amounts of free and lyophilisome-incorporated doxorubicin/
curcumin were added corresponding to 20 µM of the drug. As a control, a similar 
concentration of empty lyophilisomes was added. After 24, 48, and 72 h, medium was 
replaced, WST-1 reagent was added and incubated for 2 – 4 h at 37°C. Absorbance was 
analyzed using a Synergy 2 plate reader at 410 nm. Untreated cells served as a control. All 
experiments were performed in triplicate.
Intracellular uptake study
To study internalization of lyophilisomes, confocal microscopy was performed on living 
cells. Cells were cultured up to 80% confluency and incubated with 50 µl of lyophilisome 
suspension (lyophilisome content 125 µg/ml) for 24 h in RPMI medium containing 10% 
FCS. After incubation, cells were washed once, incubated for 5 min with CellMask orange 
(5 µg/ml) to visualize the cell membranes and then washed again, all with the same 
medium. Cells were kept at 37°C on a temperature controlled microscope stage and living 
cells were imaged immediately with a Leica SP5 confocal microscope (Leica Microsystems, 
Mannheim, Germany). FITC was excited at 488 nm and emission was collected between 
500 and 550 nm. CellMask orange was excited at 561 nm and emission was collected 
between 570 and 650 nm. Images were recorded sequentially using Leica Application 
Suite Software (Advanced Fluorescence Lite, 2.3.0. build 5131). 
Statistical analysis
Data are presented as mean with standard deviation. Drug entrapment experimental data 
were analyzed using two-tailed Student’s t-tests. Cell eliminating potential assays were 
analyzed using two way Anova Bonferroni post tests. All statistical analyses were 
performed in Graphpad Prism 5.0 (Graphpad, San Diego, CA, USA).
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RESULTS
Characterization of lyophilisomes
Lyophilisomes were prepared by a freezing, annealing and lyophilization regime, and 
analyzed by dynamic light scattering (DLS), qNano, scanning and transmission electron 
microscopy (SEM, TEM). 
The size distribution of lyophilisomes is summarized in table 1. Using DLS, the mean 
particle diameter of lyophilisomes was measured 1,695±55 nm with a polydispersity index 
of 0.726±0.035. This indicates a rather heterogeneous particle size distribution. For DLS 
it is known that larger particles will dominate smaller particles during measurement, 
resulting in a larger mean particle size. When measuring the lyophilisomes using qNano, a 
mean particle size of 1,214±79 nm was found. Using this instrument, particles smaller than 
700 nm were not detected with the specific pore used for our experiments (700 – 1,600 
nm), since they were eliminated against background levels. To investigate the lyophilisome 
preparation further, SEM was used and revealed globular structures ranging from 100 nm 
up to 3,000 nm (Fig. 1a) and TEM verified that capsules indeed contained a lumen (Fig. 1b). 
Besides capsules, sheet-like structures were formed. In order to use lyophilisomes as a 
drug delivery system they were stabilized by crosslinking in the vapor of a mixture of 
glutaraldehyde and formaldehyde. Particles thus prepared did not coagulate and no 
aggregation was observed in buffer or culture medium.    
Loading and visualization of doxorubicin and curcumin in lyophilisomes
To visualize entrapment of doxorubicin and curcumin within lyophilisomes and to 
demonstrate the drug distribution within the lyophilisomes, FITC- and Dylight 633 labeled 
lyophilisomes were used, respectively. For doxorubicin loaded FITC-lyophilisomes confocal 
microscopy showed red auto-fluorescence of doxorubicin within green-fluorescent 
lyophilisomes (Fig. 2a). Curcumin loaded Dylight 633 lyophilisomes (Fig. 2b) showed green 
auto-fluorescence of curcumin within the red-fluorescent Dylight 633 lyophilisomes. Both 
doxorubicin and curcumin showed a homogeneous distribution throughout the capsule 
lumen, but they were also visible in the capsule wall (Fig. 2a and b). The merged image 
Table 1  Size distribution of lyophilisomes
Stabilized lyophilisomes DLS qNano
Particle diameter (nm) 1,695 ± 55 1,214 ± 79
Polydispersity index 0.726 ± 0.035 N.A.a
aN.A. = Not available
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(Fig. 2a3 and b3) is an overlay of doxorubicin and curcumin in lyophilisomes (Fig. 2a2 and 
b2) and the corresponding lyophilisome image (Fig. 2a1 and b1). 
For the loading of doxorubicin and curcumin in lyophilisomes, two concentrations were 
used at room temperature, i.e. 0.1 and 1.0 mg/ml. For doxorubicin, 0.1 mg/ml resulted in an 
entrapment efficiency of 95±1%. With 1.0 mg/ml, an entrapment efficiency of 48±2% 
was obtained (Fig. 2c). Despite this lower entrapment efficiency, the absolute amount of 
doxorubicin was 5 x higher when incubated at the higher concentration. This corresponds to a 
drug loading of 0.24 and 1.2 mg doxorubicin per milligram albumin (Table 2). For curcumin, 
an entrapment efficiency of 5±2% was achieved using 0.1 mg/ml curcumin. Using 1.0 mg/ml, 
entrapment was 4±1% resulting in an 8 x higher loading of curcumin (Fig. 2d). This 
corresponds to a drug loading of 0.01 and 0.10 mg curcumin per milligram albumin (Table 2). 
As an alternative to establish the amount of doxorubicin in lyophilisomes, they were 
digested using papain resulting in the liberation of the encapsulated doxorubicin that was 
measured spectrophotometrically. Using this method, a loading efficiency of 95% was 
calculated. To verify that the anti-tumor drugs were entrapped in lyophilisomes, bare 
lyophilisomes and doxorubicin and curcumin loaded lyophilisomes were centrifuged. 
Results show clear supernatants and colored pellets for doxorubicin and curcumin, 
indicating the absence of free anti-tumor drug (Fig. 2e). Use of other temperatures (4°C, 
37°C) did not influence entrapment efficiency, which was 92 – 96% for doxorubicin and 
3 – 5% for curcumin.
Drug release studies
The drug release of doxorubicin and curcumin from lyophilisomes was studied both in 
PBS and medium supplemented with 10% FCS, for a time period up to 72 h at 4°C, room 
temperature and 37°C. The release of doxorubicin from loaded lyophilisomes was limited, 
both for PBS and medium (Fig. 3a and b). The highest release was observed at 37°C, i.e. 
Figure 1  Scanning electron microscopical image (a) and transmission electron microscopical 
image (b) of lyophilisomes, showing spherical capsules ranging from 100 up to 3000 nm. Bar represents 
10 µm in (a) and 1 µm in (b).
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Figure 2  Visualization and loading efficiency of doxorubicin and curcumin in lyophilisomes. (a and b) 
Lyophilisomes after incubation in doxorubicin containing HEPES buffer (a) or curcumin in ethanol (b) 
result in entrapment of the drug. In a4 and b4, lyophilisomes are depicted without drug to show 
their lumen. Note that since both anti-tumor drugs are also visible at wavelengths used to visualize 
lyophilisomes the lumen cannot be visualized in the presence of the drugs. The merge image (a3 
and b3) is an overlay of image (a1 and b1) and (a2 and b2). Bar represents 1 µm. c and d) Entrapment 
efficiency in lyophilisomes of doxorubicin (c) and curcumin (d) after overnight incubation of 
lyophilisomes in 0.1 and 1.0 mg/ml drug; **p<0.001. (e) Centrifuged lyophilisome suspensions 
(1: without drug; 2: with doxorubicin; 3: with curcumin) show a clear supernatant and white, red, and 
yellow pellet, indicating entrapment of the drugs.
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2.4±0.4% and 2.7±0.3% after 72 h in PBS and medium, respectively. In contrast, curcum-
in-loaded lyophilisomes showed a much higher release, i.e. in PBS 42±5% at 24 h, 50±2% 
at 48 h, and 56±2% at 72 h (Fig. 3c and d). Similar releases were obtained for medium 
(46±4% at 24 h, 52±6% at 48 h, and 55±8% at 72 h). Temperature did not influence the 
release profile of curcumin loaded lyophilisomes.
Cell viability in the presence of lyophilisomes
In order to investigate whether lyophilisomes are cytocompatible, empty lyophilisomes 
were administered to cells in ascending concentrations, ranging from 0 to 1,000 µg/ml. 
Cell viability was not compromised as indicated by a WST-1 proliferation assay showing 
comparable values for SKOV-3 and HeLa cells with and without lyophilisomes (Fig. 4). 
Despite coverage of cells by lyophilisomes, also no detectable morphological changes 
were visible at the light microscopical level (data not shown).
Intracellular uptake of lyophilisomes
The ability of lyophilisomes to be internalized by cells was studied by confocal microscopy. 
HeLa cells were incubated with lyophilisomes and after 24 h uptake of lyophilisomes was 
observed (Fig. 5). When incubated with lyophilisomes, cells clearly contained green 
fluorescent hollow spheres at 24 h, representing the lyophilisomes (Fig. 5b). The plasma 
membrane dye CellMask further indicated that the lyophilisomes were indeed internalized 
and not merely associated with the plasma membrane. In addition, the corresponding 
bright field image showed that lyophilisomes did not lead to detectable morphological 
changes of the cells (Figure 5c and d), further corroborating the absence of cytotoxic effects.
Cell eliminating potential of lyophilisomes loaded with doxorubicin  
or curcumin
To compare the cell eliminating potential of both anti-tumor drug loaded lyophilisomes, 
a WST-1 proliferation assay was used. A concentration of 20 µM of free doxorubicin or free 
curcumin was required to eliminate SKOV-3 and HeLa cells, respectively. To assess the 
Table 2  Drug entrapment in lyophilisomes
Drug Content used for loading experiments
(mg drug/ml)
Drug loading
(mg drug/mg albumin)
Doxorubicin 0.1 mg/ml 0.24
1.0 mg/ml 1.20
Curcumin 0.1 mg/ml 0.01
1.0 mg/ml 0.10
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effect of doxorubicin and curcumin loaded lyophilisomes on tumor cells, equivalent 
amounts of free and drug loaded lyophilisomes were used. As a control, a similar 
concentration of empty lyophilisomes was employed. Due to the high entrapment 
efficiency, doxorubicin loaded lyophilisomes with 0.1 mg/ml loading concentration were 
used. Since curcumin had a lower entrapment efficiency, lyophilisomes loaded with a 1.0 
mg/ml curcumin solution were applied. Lyophilisome contents correspond to 50 – 100 
µg/ml lyophilisomes, a concentration at which cell viability is ensured (Fig. 4).
Figure 3  Drug release from doxorubicin and curcumin loaded lyophilisomes in PBS and medium. 
(a and b) Lyophilisomes were incubated in 0.1 mg/ml doxorubicin in HEPES buffer, washed three times, 
and release was analyzed in PBS and medium. A similar release profile was obtained for PBS (a) and 
medium (b) with a maximum release of 2.4±0.4% and 2.7±0.3% after 72 h. (c and d) Curcumin release 
profiles of loaded lyophilisomes after incubation in 1.0 mg/ml curcumin in ethanol and washing three 
times. Curcumin release was 56±2% and 55±8% after 72 h in PBS and medium, respectively. Note variation 
in the range of y-axis.
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Figure 4  Cell viability of SKOV-3 and HeLa cells after incubation with lyophilisomes. Cells were 
exposed to various contents of empty lyophilisomes and cell viability assays (WST-1) were performed 
after 72 h. Cell viability was not affected by the presence of lyophilisomes.
Figure 5  Cellular uptake of lyophilisomes studied by confocal laser scanning microscopy. HeLa 
cells were cultured in an 8-well microscopy chamber to 80% confluency and treated without (a and c) and 
with (b and d) lyophilisomes for 24 h. Note internalization of lyophilisomes (b). Inset: magnification 
of internalized lyophilisomes. Green fluorescence corresponds with FITC-lyophilisomes and 
fluorescence of CellMask orange is shown in red. Bright field images (c and d) show general 
morphology of the cells. The scale bar represents 20 µm in (a-d) and 2 µm in inset (b).
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Exposure to doxorubicin-loaded lyophilisomes (corresponding to 20 µM free doxorubicin) 
inhibited SKOV-3 ovarian cancer cell growth in a time-dependent manner (Fig. 6a). Similar 
inhibition of cell proliferation was observed for free doxorubicin and entrapped 
doxorubicin, where entrapped doxorubicin only resulted in lower SKOV-3 cell viability at 
24 h (p<0.05). After 72 h of culture, cell viability had decreased to 6% in comparison to 
cells treated with non-loaded lyophilisomes.
Figure 6  Time dependent effect of doxorubicin and curcumin loaded lyophilisomes on cell 
viability of SKOV-3 (a) and HeLa cells (b). Similar dosages of free doxorubicin/curcumin and doxorubicin/ 
curcumin containing lyophilisomes were used, and cell viability was assayed using WST-1. (a) SKOV-3 
cells generally responded to doxorubicin loaded lyophilisomes in a similar fashion as free doxorubicin. 
(b) HeLa cells showed a more pronounced response to curcumin loaded lyophilisomes compared 
to free curcumin at later time points. *p<0.05 **p<0.001.
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When HeLa cells were incubated with curcumin loaded lyophilisomes (corresponding to 
20 µM free curcumin) also a decrease in cell viability was observed. Curcumin loaded 
lyophilisomes exerted a more pronounced effect on the cancer cells as compared to free 
curcumin after 24 h (p<0.05), 48 h and 72 h (p<0.001; Fig. 6b). After 72 h of culture, cell 
viability had decreased to 2% in comparison to cells treated with non-loaded lyophilisomes. 
The low cell viability results for both SKOV-3 and HeLa cells after incubation with loaded 
lyophilisomes were consistent with the small remaining number of cells observed by light 
microscopy (data not shown).
DISCUSSION
In the past decade, the field of drug delivery for cancer has been revolutionized with the 
advent of nanotechnology, and biocompatible nanoparticles have been developed as 
systemic carriers for therapeutic compounds to target specific cells and tissues. Numerous 
investigations have been conducted to develop more efficient systems for drug delivery. 
The most important challenge in the formulation of drug delivery systems involves the 
preparation of carrier systems that are capable of encapsulating the desired drug and 
deliver it to the tumor tissue in its active form. Liposomes constitute an effective drug 
delivery system, as exemplified by Doxil [28]. However, their chemical and physical 
instability during manufacturing and storage still poses a challenge [29]. In a quest for 
stable and efficient carrier systems for anti-tumor agents, we have developed a drug 
delivery system named ‘lyophilisomes’ [5]. The process to produce lyophilisomes is 
physical rather than chemical in nature, and allows for the use of biological macromolecules, 
including proteins, as the wall material. Nanoparticles made from albumin are well 
tolerated by the body, as indicated by clinical studies with FDA approved albumin nano/
micro particle formulations such as Albunex [30,31] and Abraxane [32,33].
Albumin is the main protein in the plasma and is best known for its remarkable ligand 
binding capacity, providing an arsenal of compounds with favorable, noncovalent 
reversible binding characteristics for transport in the body and release at the cell surface 
[34,35]. Potential drug loading mechanisms include electrostatic attraction and 
hydrophobic interactions. Moreover, albumin drug delivery systems offer possibilities for 
surface modification due to the presence of functional groups (i.e. carboxylic and amino 
groups) enabling specific drug targeting to the site of action [35]. Albumin-based systems 
are considered safe since they are metabolizable in vivo by digestive enzymes into 
innocuous peptides whereas synthetic polymers may give harmful degradation products 
[6]. In addition, albumin is thought to facilitate endothelial transcytosis of unbound and 
albumin-bound plasma constituents into the extravascular space. This process is initiated 
by binding of albumin to a cell surface, 60-kDa glycoprotein (gp60) receptor [36].
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In this study we prepared albumin-based lyophilisomes. Even large numbers of 
lyophilisomes did not affect SKOV-3 and HeLa cell viability. After 24 h lyophilisomes were 
internalized by HeLa cells, without changes in proliferation or morphology, indicating that 
they are non cytotoxic. Quite interestingly, this uptake occurred in the absence of an inter-
nalization signal such as a receptor ligand or a cell-penetrating peptide. It remains to be 
shown in which way such modifications would modulate uptake kinetics and/or efficiency.
To investigate whether lyophilisomes could be used for drug delivery, we used doxorubicin 
and curcumin as model drugs and analyzed their incorporation into lyophilisomes. This 
procedure was based on diffusion of the drug into the capsule. Interestingly, doxorubicin 
loaded lyophilisomes resulted in a high entrapment efficiency (95%) together with a very 
low release (2 – 3% after 72 h). This effect cannot be explained by the process of simple 
diffusion. Albumin is known as an important transport protein and has several binding sites 
for hydrophobic compounds, which may explain the affinity of albumin for doxorubicin, 
maintaining the drug within lyophilisomes [37,38]. Albumin-based lyophilisomes may be 
a suitable delivery system for this drug and doxorubicin loaded lyophilisomes may be 
prepared upfront and stored at 4°C or in a lyophilized state. Next to doxorubicin, we also 
analyzed the drug curcumin. The entrapment efficiency of curcumin was quite low (4%) 
and release was rather fast (±55% after 72 h). Similar release profiles have been observed 
for curcumin in other nanoparticle systems, e.g. alginate-chitosan-pluronic composite, 
PLGA, and polymeric nanoparticles [23,39,40]. To retain the drug within the lyophilisomes 
for a longer time, lyophilisomes may be further crosslinked after loading which will make 
the capsule’s wall less porous and may result in a better retention of curcumin. 
In order to investigate the cell eliminating potential of our formulations, SKOV-3 and HeLa 
cells were treated with lyophilisomes loaded with doxorubicin or curcumin, respectively. 
Doxorubicin-loaded lyophilisomes showed a profound cytotoxic effect similar to free 
doxorubicin (20 µM in culture medium). This activity was contrasted with the low release 
of the drug from doxorubicin-loaded lyophilisomes in PBS or medium (3% of 20 µM is 0.6 
µM). This concentration is likely not sufficient to induce cell death. An explanation for the 
efficacy of loaded lyophilisomes may be their internalization into the cell, followed by 
drug release inside the cell, which may be assisted by the action of endogenous 
proteinases. Alternatively, the albumin wall of lyophilisomes attached to the outside of the 
cell may be damaged (e.g. by excreted enzymes) to locally release high doses of 
doxorubicin resulting in elimination of cells. For curcumin-loaded lyophilisomes, which 
are more effective than free curcumin, a similar effect may be put forward: local release of 
curcumin and internalization of drug-loaded lyophilisomes. It should be noted that the 
wall of the lyophilisomes can be made from any protein, and can be adapted to the type 
of drug and the proteases / microenvironment of specific tumor cells. 
Before drug delivery systems reach the target site, they need to travel through the vascular 
bed. Particle size has a fundamental effect on biodistribution [41]. For cancer, an effective 
strategy is based on the enhanced permeability effect (EPR) associated with hyper-
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permeability of tumor vasculature and lack of lymphatic drainage [42]. Nanoparticles 
usually do not extravasate through normal endothelium since tight endothelial junctions 
(5 – 10 nm) between endothelial cells prevent extravasations of small particles [43]. 
However, due to the EPR effect, nanoparticles (<500 nm) can extravasate from the blood 
vessels to the tumor and accumulate, creating high local drug concentrations [44]. The 
cut-off size for permeability in individual tumor varies between 200 and 800 nm [45]. 
Lyophilisomes have a rather large size distribution, ranging from 100 to 3,000 nm. A next 
step is therefore to size them to appropriate diameters to make them more suitable to 
employ the enhanced permeability effect in tumors and functionalize the capsules with 
targeting molecules to increase specificity.
CONCLUSIONS
This study demonstrates the potential of albumin-based lyophilisomes as a drug delivery 
system. Both doxorubicin and curcumin-loaded lyophilisomes were capable of efficiently 
eliminating tumor cells in vitro. 
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Table S1  Specifics on freeze drying program.
Step 1 Freeze / °C -10
Freeze / min 60
Freeze / mbar -
Step 2 Freeze / °C -13
Freeze / min 60
Freeze / mbar -
Step 3 Freeze / °C -16
Freeze / min 60
Freeze / mbar -
Step 4 Freeze / °C -20
Freeze / min 60
Freeze / mbar -
Step 5 Product 1 / °C -20
Product 2 / min -20
Product 3 / mbar -20
Step 6 Heating / °C -20
Heating / min 30
Heating / mbar 0.8
Step 7 Heating / °C -20
Heating / min 300
Heating / mbar 0.8
Step 8 Heating / °C -20
Heating / min 180
Heating / mbar 0.8
Step 9 Heating / °C -0.1
Heating / min 1
Heating / mbar 0.8
Step 10 Heating / °C -0.1
Heating / min 210
Heating / mbar 0.8
Step 11 Heating / °C 20
Heating / min 90
Heating / mbar 0.8
Step 12 Heating / °C 0
Heating / min 0
Heating / mbar 0
Step 13 Drying / °C 20
Lyophilisomes are put  
in the freeze dryer
Start lyophilization
End lyophilization
Annealing step
Lyophilization
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ABSTRACT
Lyophilisomes are a novel class of proteinaceous biodegradable nano/micro drug delivery 
capsules prepared by freezing, annealing and Iyophilization. In the present study, 
lyophilisomes were functionalized for active targeting by antibody conjugation in order 
to obtain a selective drug-carrier system. Lyophilisomes were vapor crosslinked for 2 h, 
resulting in stable capsules, while leaving sufficient primary amines for further modification. 
The humanized KC4 (hKC4) antibody was conjugated to lyophilisomes to achieve specific 
targeting to mucin 1 (MUC1)-over expressing tumor cells. For this, thiolated antibodies 
were conjugated to maleimide- activated lyophilisomes, resulting in an hKC4 specific drug 
targeting system towards MUC1-overexpressing human ovarian and cervical tumor cells. 
FACS analysis demonstrated that hKC4-conjugated lyophilisomes bound specifically to 
MUC1-overexpressing tumor cells (HeLa, OVCAR-3, and SKOV-3 cells), compared to MUC1- 
negative cells (LS174T). In addition, control non-specific IgG-conjugated lyophilisomes did 
not bind to MUC1- overexpressing tumor cells. When MUC1- positive and -negative cells 
were combined in one culture, hKC4-conjugated lyophilisomes specifically targeted MUC1- 
positive cells, whereas negative cells showed merely background levels. Transmission 
electron micro - scopy showed uptake of hKC4-conjugated lyophilisomes via phagocytosis or 
 macro - pinocytosis. In conclusion, hKC4-conjugated albumin-based lyophilisomes represent 
a potential drug delivery system for targeted drug transport to MUC1-over expressing 
tumor cells.
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INTRODUCTION
Chemotherapy is a standard treatment for cancer, but its efficacy is often limited due to 
associated adverse effects. In recent years, new strategies for cancer treatment have 
emerged which are based on drug delivery systems. These systems include drug carriers 
for specific transport of anti-cancer drugs to the tumor site, such as liposomes and 
polymersomes [1,2]. However, the limited chemical and physical stability of such capsules 
during manufacturing and storage still pose a challenge [3,4]. Besides optimizing current 
nanoparticle systems, research on new drug delivery systems continues. The abundant 
interest shown in the field of drug delivery is illustrated by the development of numerous 
drug delivery systems over the last decade [5]. Lyophilisomes, a novel drug delivery 
capsule in the nano/micrometer range, may become a new generation of drug delivery 
systems [6]. 
Lyophilisomes can be prepared from a diversity of water-soluble macromolecules (e.g. 
albumin, elastin, and heparin) by freezing, annealing, and lyophilization regimens. This 
makes it possible to manufacture lyophilisomes with different properties, resulting in an 
adaptable carrier system towards various applications. The system is highly flexible, 
allowing the incorporation of virtually any biomolecule in the wall and/or lumen. For 
instance, enzymes incorporated in the capsule wall and the lumen demonstrated they 
could still exert their biological activity, partly due to mild preparation conditions [7]. We 
have already shown that lyophilisomes can be efficiently loaded with doxorubicin, 
resulting in tumor cell elimination [6]. Drugs can be entrapped by diffusional loading after 
preparation of the capsules, thus separating the crosslinking step from the drug loading 
step. Using this procedure, biomolecules are not exposed to harsh conditions, such as an 
acid environment preventing deactivation of biomolecules. Furthermore, lyophilisomes 
possess a relatively thick wall that can be loaded with enzymes that upon degradation 
may activate a prodrug in the lumen at the site of interest. Due to these properties, 
lyophilisomes can be utilized to design multifunctional systems for the delivery of 
therapeutic agents. 
In this study, albumin-based lyophilisomes were used. Albumin has been used as a drug 
carrier because of its ample availability, its lack of toxicity and immunogenicity, and its 
biodegradability [8,9]. In addition, it is likely that albumin, with a half-life of 19 days in 
circulation, may play an important role for improving the pharmacokinetics and targeting 
properties of drugs, for instance because of its preferential uptake in tumors [8]. In contrast 
to nanoparticulate systems from e.g. polymers, albumin offers the benefit of carrying 
natural functional groups (e.g. amine and carboxylic groups) that can be used for surface 
modification [10,11]. In a previous study we noticed that albumin-based lyophilisomes did 
not affect cell viability [6]. The FDA-approved products, Albunex [12,13] and Abraxane 
[14,15], demonstrate that albumin nano/micro particles are well-tolerated in humans. 
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The potential of nanoparticles to act as a drug delivery system mainly comprises passive 
tumor targeting. Passive targeting results from the “enhanced permeability and retention 
(EPR) effect” characterized by enhanced accumulation of nanoparticles in tumors due to 
leaky tumor vasculature in combination with impaired lymphatic drainage [16]. An active 
targeting effect can be achieved if a targeting ligand is conjugated to the surface of the 
drug delivery carrier. Specific targeting can improve binding kinetics and result in a more 
efficient uptake of the anti-cancer drug [17–19].
To probe the possibility of using lyophilisomes for specific tumor targeting, antibodies to 
mucin 1 (MUC1) were conjugated to lyophilisomes. MUC1 is a highly glycosylated type 1 
transmembrane glycoprotein that functions as a signal transducer and is involved in 
cancer progression [20,21]. Cancer cells of various origin express high levels of MUC1, such 
as cancers of the ovary, cervix, colon, prostate, breast, lung, and pancreas, making it a 
suitable target for chemotherapeutics, while expression on healthy cells is low [22–24]. In 
this study, antibody-conjugated lyophilisomes were prepared to investigate the specific 
targeting potential towards MUC1-overexpressing human ovarian and cervical tumor cells.
MATERIALS & METHODS
Materials
Bovine serum albumin was purchased from PAA Laboratories (Linz, Austria). Fluorescein 
isothiocyanate (FITC)-conjugated bovine albumin and non-specific human IgG from 
human serum were purchased from Sigma Aldrich (Steinheim, Germany). Sulfo-N-[g- 
maleimidobutyryloxy]sulfosuccinimide ester (sulfo-GMBS) and 2-iminothiolane reagent 
were purchased from Pierce Biotechnology (Rockford, IL, USA). Glutaraldehyde and 
formaldehyde were obtained from Merck (Darmstadt, Germany). 
Methods
Preparation of lyophilisomes
Albumin lyophilisomes were prepared as described [6]. Briefly, droplets of a solution of 
0.25% (w/v) bovine serum albumin (BSA) in 0.01 M acetic acid were frozen in liquid nitrogen 
(-196°C). The frozen albumin preparation was incubated at -10 to -20°C for 3 h (annealing 
step), and subsequently lyophilized. This procedure results in hollow nano/micro spheres 
(“lyophilisomes”). In order to visualize the lyophilisomes, FITC-conjugated albumin was 
added to non-labeled albumin (1:10) in the starting solution. To obtain stabilized 
lyophilisomes, they were vapor crosslinked with glutaraldehyde and formaldehyde. 
Generally we use 40 ml of a 0.25 % BSA solution, which corresponds to 100 mg albumin 
(2.5 mg/ml). The final lyophilisome population was centrifuged three of four times at low 
speed (60x g; Thermo, Heraeus Fresco 17; Newport Pagnell, Great Britain) to remove large 
lyophilisomes and sheet-like structures, until no pellet was observed. After this procedure, 
about 30% of the original weight of lyophilisomes remained. Lyophilisomes (1 mg/ml) 
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were stored in 0.1% (v/v) Tween-20 (Sigma Aldrich, Steinheim, Germany) in phosphate 
buffered saline (PBS-T, pH 7.4).
Particle size measurements
Two methods were used to determine lyophilisome size: dynamic light scattering (DLS) 
and qNano [6,25]. For DLS, stabilized lyophilisomes were dispersed in 0.1% (v/v) PBS-T (pH 
7.4) and analyzed using a Zetasizer Nano-S (Malvern Instruments Ltd, Malvern, UK). For 
qNano (Izon, Science Ltd., Burnside, New Zealand), a pore size of 600 – 2,000 nm was used 
to ensure a continuous flow of particles. Data were analyzed with Izon Control Suite 2.1 
software.
Quantification of amine group content on lyophilisomes
Primary amine groups were utilized in the vapor crosslinking step to stabilize the 
lyophilisomes. Primary amines are also necessary to conjugate antibodies to the 
lyophilisomes. To determine the amount of remaining primary amines after stabilization, 
a 2,4,6-trinitrobenzene sulfonic acid (TNBS) assay was performed. The amine group 
content of lyophilisomes was determined spectrophotometrically at 420 nm with a 
standard curve of glycine [26].
Optimization and quantification of thiol groups on antibodies
In order to conjugate antibodies to lyophilisomes, a sulfhydryl group was introduced on 
the antibody that can react with maleimide-modified lyophilisomes. To determine the 
amount of reactive sulfhydryl groups on antibodies, Ellman’s reagent was used [27,28]. The 
quantification was performed immediately after modifying the antibodies to prevent 
dimerization by oxidative disulfide bridge formation. 
One ml of 1 mg/ml antibody solution in 2 mM ethylenediaminetetraacidic acid (EDTA) in 
phosphate-buffered saline (PBS; pH 8.0) was incubated with 4.7 µl (10-fold molar excess), 
11.9 µl (25-fold molar excess), 23.8 µl (50-fold molar excess), or 47.6 µl (100-fold molar 
excess) of 2 mg/ml 2-iminothiolane (Traut’s reagent), for 2, 5 and 16 h under rotation (36 
rpm, “Assistant” Rotating mixer, Karl Hecht, Sondheim, Germany) at room temperature. 
The antibody was purified on SephadexTM G-25M desalting columns (GE Healthcare, Buck-
inghamshire, UK) using 2 mM EDTA in PBS (pH 8.0) as eluent. The protein-containing 
fractions were identified spectrophotometrically at 280 nm with the NanoDrop 2000c 
(Thermo Scientific, Wilmington, DE, USA) and pooled. This solution was concentrated to 
approximately 1 mg/ml using Amicon Ultra 5k centrifugal filter devices (Millipore, Darmstadt, 
Germany). Aliquots (250 µl) of concentrated antibody were incubated in 6.25 µl of Ellman’s 
reagent (4 mg/ml in sodium phosphate buffer, pH 8.0) for 15 min at room temperature 
and measured spectrophotometrically using a Synergy 2 plate reader at 412 nm (Biotek, 
Winooski, VT) with a calibration curve of L-cysteine. For antibody conjugations at pH 7.2, a 
50-fold molar excess of Traut’s reagent was tested after incubation for 2, 5 and 16 h.
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Antibody conjugation to lyophilisomes
A schematic representation of the reactions is depicted in figure 1.
Reaction 1: Activation of lyophilisomes. A suspension of 1 ml lyophilisomes (1 mg/ml) in 
0.1% (v/v) PBS-T (pH 7.4) was centrifuged (5 min, 17,000x g, 4°C). To obtain maleimide- 
activated lyophilisomes, 1 mg lyophilisomes was resuspended in 1 ml PBS-T and incubated 
overnight with 31.1 µl of 10 mM sulfo-GMBS in PBS-T (pH 8.0) at 4°C on a rotator (36 rpm), 
resulting in a 20-fold molar excess of sulfo-GMBS in relation to albumin. Excess sulfo-GMBS 
was removed by centrifugation using three washing steps in PBS-T (pH 7.4). 
Reaction 2: Thiolation of antibodies. To introduce sulfhydryl groups on hKC4 antibodies and 
non-specific control IgG antibodies, 1 ml of 1 mg/ml antibody solution was incubated in 
PBS (pH 7.2) with a 50-molar excess of Traut’s reagent and incubated for 5 h at room 
temperature on a rotator (36 rpm). Antibodies were purified using a SephadexTM G-25M 
desalting column. The protein-containing fractions were measured spectrophotometri-
cally with the NanoDrop at 280 nm and pooled. This solution was concentrated using 
Amicon Ultra 5k centrifugal filter devices to a final concentration of approximately 1 mg-ml 
in 2 mM EDTA in PBS (pH 6.5). This procedure generates a thiolated antibody reactive 
towards a maleimide crosslinker. Thiolated antibodies were immediately used for the 
conjugation reaction to lyophilisomes to prevent dimerization.
Reaction 3: Conjugation of antibodies to lyophilisomes. For the coupling reaction, 1 ml of 
1 mg/ml sulfhydryl-reactive lyophilisomes was centrifuged and conjugated in 1 ml to 
thiolated hKC4 or non-specific IgG control antibody (both 1 mg/ml) in 2 mM EDTA in PBS 
(pH 6.5). Non-coupled antibodies were removed by centrifugation (5 min, 17,000x g, 4°C) 
using three washing steps in PBS-T (pH 7.4).  Antibody-conjugated lyophilisomes were 
stored at 4°C in the dark.
To verify antibody conjugation, antibody-conjugated lyophilisomes were incubated with 
a goat-anti-human fluorescent IgG (Alexa 594 nm; 10 µg/ml) for 1 h at room temperature under 
rotation (36 rpm) in the dark, and subsequently washed three times with 0.2% BSA in PBS. 
Lyophilisomes were deposited on poly-D-lysine-coated cover slips and analyzed by 
fluorescent microscopy (Leica DM 6000 B, Leica Microsystems, Wetzler, Germany).
Cell culture
All culture media were purchased from Gibco (Karlsruhe, Germany) unless indicated 
otherwise. The human ovarian cancer cell lines OVCAR-3 and SKOV-3 were cultured in 
DMEM GlutaMAX and McCoy’s 5A GlutaMAX, respectively, supplemented with 10% (v/v) 
fetal calf serum (FCS; PAA Laboratories, Pasching, Austria). The human cervical tumor cell 
line, HeLa, and the human colon adenocarcinoma cell line, LS174T, were cultured in RPMI 
1640 GlutaMAX medium supplemented with 10% (v/v) FCS. The cells were cultured in a 
humidified atmosphere with 5% CO
2
 at 37°C. Subconfluent cells were dissociated with 
0.05% (w/v) trypsin in 0.02% (w/v) EDTA in PBS (PAA Laboratories) and were maintained as 
proliferating cultures. 
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For FACS analysis, cells were stained with the cell membrane dye PKH26 (Sigma Aldrich, 
Missouri, USA) [29,30]. One million cells were incubated in 2 µM PKH26 dye in 500 µl buffer 
(Diluent C, provided by manufacturer) for 5 min. To stop the staining reaction, 500 µl FCS 
was added and incubated for 5 min. Subsequently, cells were washed three times with 
culture medium and cultured for one day prior to experiments.
MUC1 expression of ovarian and cervix tumor cell lines
In order to investigate the MUC1 antigen expression of OVCAR-3, SKOV-3, HeLa, and LS174T 
tumor cell lines, 60,000 cells were incubated with 10 µg/ml hKC4 antibody in an Eppendorf 
tube for 1 h at room temperature under rotation (36 rpm) in the dark. Subsequently, cells 
were washed three times with 0.2% BSA in PBS and incubated with a goat-anti-human 
fluorescent IgG (Alexa 594 nm; 10 µg/ml) for 1 h at room temperature under rotation (36 
rpm) in the dark and subsequently washed three times with 0.2% BSA in PBS and analyzed 
with the FACScaliber (Becton Dickinson, Breda, Netherlands) and Flowjo software (FlowJo, 
Ashland, OR, USA).
Binding of antibody-conjugated lyophilisomes
To investigate the binding of hKC4-conjugated lyophilisomes, MUC1 overexpressing 
OVCAR-3, SKOV-3 and HeLa cells were used. The MUC1-negative cell line, LS174T, served as 
a control. An aliquot of 25 µl of lyophilisomes (lyophilisome content 40 µg/ml) conjugated 
to (non-)specific antibody was added to 60,000 PKH26 stained cells in an Eppendorf tube 
and incubated for 1 h at room temperature under rotation (36 rpm). In addition, an excess 
of free MUC1 antibody (10 µg/ml) was added to the cells 1 h prior to the incubation with 
hKC4-conjugated lyophilisomes. Cells were washed three times with 0.2% BSA in PBS and 
analyzed with the FACScaliber (Becton Dickinson, Breda, Netherlands) and Flowjo software 
(FlowJo, Ashland, OR, USA). FACS settings were determined so that cells not associated 
with lyophilisomes were depicted below a fluorescent signal of 101 and regarded as 
negative. When lyophilisomes were associated with cells, the fluorescent signal became 
higher than 101 and these cells were regarded as positive. Data were analyzed by GraphPad 
Software 5.0 (Graphpad, San Diego, CA, USA). 
Binding of antibody-conjugated lyophilisomes to mixed cell cultures 
In order to examine whether hKC4-conjugated lyophilisomes bound specifically to MUC1 
expressing tumor cells, both MUC1-positive and -negative cells were mixed (1:1) before 
exposure to lyophilisomes. To visualize cells, all nuclei were stained with 4’,6-diamidi-
no-2-phenylindole (DAPI) [31]. To differentiate between both cell lines, MUC1-positive cells 
were stained with PKH26. 25 µl of lyophilisomes (40 µg/ml) conjugated with specific and 
non-specific antibody were incubated with 60,000 cells (30,000 MUC1-positive cells and 
30,000 MUC1-negative cells) for 1 h at room temperature under rotation (36 rpm). 
Subsequently, cells were fixed in 4% paraformaldehyde and cytospins were made. FACS 
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analysis was performed using FACScaliber and Flowjo software. Confocal images were 
obtained using an Olympus FV-1000 confocal microscope (Olympus GmbH, Hamburg, 
Germany) and analyzed with FV 10-ASW 1.6 viewer software. Data were analyzed by 
GraphPad Software 5.0.
Cell binding and uptake of antibody-conjugated lyophilisomes visualized  
by transmission electron microscopy
MUC1-positive and -negative cells were incubated with 25 µl of lyophilisomes (lyophilisome 
content 40 µg/ml) conjugated with (non-)specific antibody for 1 h under rotation (36 rpm). 
Subsequently, cells were embedded in 1.5% (w/v) agarose, fixed in 2% (v/v) glutaraldehyde 
in 0.1 M phosphate buffer (pH 7.4), post-fixed with 1% (w/v) osmium tetroxide, dehydrated 
in an ascending series of ethanol, and embedded in Epon 812. Ultrathin sections (60 nm) 
were cut and picked up on Formvar-coated grids, post-stained with lead citrate and uranyl 
acetate, and examined in a JEOL 1010 transmission electron microscope (Tokyo, Japan).
Statistical analyses
Data are presented as mean with standard deviation. Data of sections ‘Particle size 
measurements of lyophilisomes’, ‘Optimizing vapor crosslinking on lyophilisomes for 
antibody conjugation’, ‘Thiolation of IgG antibody’ and ‘Binding of antibody-conjugated 
lyophilisomes’ were analyzed using two-tailed Student’s t-tests. All statistical analyses 
were performed in Graphpad Prism 5.0 (Graphpad, San Diego, CA, USA).
RESULTS
To probe the possibility of using lyophilisomes for specific tumor targeting, lyophilisomes 
were modified with antibodies using the heterobifunctional crosslinker sulfo-GMBS in 
combination with Traut’s reagent (Fig. 1).
Particle size measurements of lyophilisomes
The size distribution of lyophilisomes is summarized in Table 1. Using DLS, the mean 
particle diameter of lyophilisomes was measured 1,561±49 nm with a polydispersity index 
of 0.7±0.03. This indicates a rather heterogeneous particle size distribution. For DLS, it is 
known that larger particles will dominate smaller particles in the measurement, resulting 
in an overestimated mean particle size. When measuring the lyophilisomes using qNano, 
a mean particle size of 1,160±75 nm was found. With this instrument, particles smaller than 
600 nm were not detected with the specific pore used for our experiments (600 – 2,000 nm), 
as they became background signal. The standard deviations in Table 1 are rather small 
since the data are determined using the absolute mean value of multiple experiments. 
To visualize the size range of lyophilisomes in more detail, a typical size distribution measured 
by qNano is depicted in figure 2.
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Antibody conjugation did not influence mean particle diameter, as DLS measured a mean 
particle diameter of 1,426±68 with a polydispersity index of 0.8±0.04 and qNano measured 
a mean particle diameter of 1,256±84 (Table 1). 
Optimizing vapor crosslinking on lyophilisomes for antibody conjugation
Albumin contains approximately 1,000 nmol amine groups/mg. In lyophilisomes, these 
functional groups were partially used to stabilize lyophilisomes by vapor crosslinking with 
glutaraldehyde and formaldehyde. The percentages of primary amines that remained on 
lyophilisomes were 66±7%, 58±9%, and 37±7% after vapor crosslinking for 2, 8, and 16 h, 
respectively (Fig. 3). 
Figure 1  Schematic illustration of lyophilisome conjugation with antibody. (1) Free amine groups 
of lyophilisomes react with sulfo-GMBS introducing reactive maleimide groups. (2) Antibodies are 
modified with 2-iminothiolane (Traut’s reagent) introducing reactive sulfhydryl groups, resulting in 
thiolated antibodies. (3) Thiolated antibodies are conjugated to pre-activated maleimide-lyophili-
somes, resulting in stable antibody conjugation to lyophilisomes. In this study, hKC4 antibodies were 
used to actively target cancers overexpressing MUC1 antigen, using non-specific human IgG’s as a 
control antibody.
Table 1  Size distribution of lyophilisomes before and after antibody conjugation
Stabilized lyophilisomes DLS qNano DLS qNano
Before Ab conjugation After Ab conjugation
Mean Particle diameter (nm) 1,561 ± 49 1,160 ± 75 1,426 ± 68 1,306 ± 84
Polydispersity index 0.698 ± 0,029 N.A.a 0.784 ± 0,042 N.A.a
aN.A. = Not available
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Figure 2  Size distribution of non-modified lyophilisomes as measured by qNano.
Figure 3  Effect of vapor crosslinking on the percentage of remaining primary amine groups 
on lyophilisomes. Lyophilisomes were crosslinked in a vapor mixture of glutaraldehyde and 
formaldehyde for 2, 8, and 16 h. The number of primary amine groups was spectrophotometrically 
detected using a TNBS assay. The absolute amine group content of albumin is 1061±78 nmol/mg. 
After vapor crosslinking for 2, 8, and 16 h, 66±7%, 58±9%, and 37±7% of the amine groups remained 
available, respectively. *p<0.05 **p<0.01.
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Stabilized lyophilisomes -independent of time of stabilization- did not dissolve upon 
wetting. For this study, we chose to use a 2 h vapor crosslinking step for lyophilisomes, 
since most amine groups were preserved using this incubation time, allowing further 
modification.
Thiolation of IgG antibody
To conjugate hKC4 anti-MUC1 antibodies to lyophilisomes, sulfhydryl groups were 
introduced on the antibody by Traut’s reagent. Non-specific human IgG’s were used to 
determine the optimal conditions to introduce sulfhydryl groups. As depicted in figure 4, 
increasing the molar excess of Traut’s reagent resulted in a significantly increased number 
of thiol groups per antibody. Similar results were obtained for longer incubation times. 
However, no differences were observed between 5 and 16 h incubation, possibly due to 
an increase in disulfide bridging. Ideally, the number of thiol groups should range between 
one and two per antibody to allow efficient conjugation and preserve antibody function 
[17]. Therefore, the optimal incubation conditions were 50-fold molar excess for 2 h, which 
resulted in 2.0±0.3 thiol groups per antibody.
Figure 4  The number of sulfhydryl groups introduced on non-specific human IgG’s by 
2-iminothiolane (Traut’s reagent) using different incubation times and different amounts of Traut’s 
reagent. With increased molar excess of Traut’s reagent and longer incubation time, the number of 
thiol groups on non-specific human IgG’s increased, with the exception of the 16 h incubation time, 
possibly due to disulfide bridging. *p<0.01 **p<0.001.
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These experiments were performed at pH 8.0. However, our antibody was dissolved in PBS 
with a pH of 7.2. The thiolation reaction occurred less efficient at pH 7.2, resulting in fewer 
sulfhydryl groups introduced per antibody. Reaction with a 50-fold molar excess of Traut’s 
reagent for 2, 5 and 16 h resulted in 0.5±0.1, 1.3±0.2 and 1.5±0.4 thiol groups per antibody, 
respectively. For further experiments, the antibody conjugation conditions at pH 7.2 were 
therefore altered to 50-fold molar excess for 5 h.
Antibody conjugation to lyophilisomes
hKC4 is a humanized monoclonal antibody directed against MUC1, which is overexpressed 
by several tumor cells. To show that antibody conjugation was successful, lyophilisomes 
were studied with fluorescent microscopy. Unmodified lyophilisomes were green without 
Figure 5  Antibody conjugation to lyophilisomes visualized by fluorescence microscopy. Green 
fluorescence corresponds to FITC-labeled lyophilisomes. Red fluorescence corresponds to antibodies 
conjugated to lyophilisomes. a and b) Unmodified lyophilisomes without antibody. c and d) 
Lyophilisomes conjugated with hKC4 antibody. e and f) Lyophilisomes conjugated with non-specific 
human IgG as a control antibody. The scale bar represents 10 µm.
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red fluorescence, indicating the absence of antibodies (Fig. 5a and b). hKC4-conjugated 
lyophilisomes showed both green and red fluorescence, confirming the presence of hKC4 
antibodies to lyophilisomes (Fig. 5c and d). As a control antibody, a non-specific human 
IgG antibody was conjugated to lyophilisomes and its presence was also confirmed by 
fluorescent microscopy (Fig. 5e and f).
Binding of antibody-conjugated lyophilisomes
MUC1 overexpressing tumor cell lines, OVCAR-3, SKOV-3 and HeLa, showed MUC1 antigen 
expression with a mean fluorescence value of 805±188, 232±112, and 228±56, respectively. 
The MUC1-negative tumor cell line (LS174T) only gave a mean fluorescence value of 5±1 
(Table 2).
MUC1-positive and -negative cell lines were incubated with hKC4-conjugated lyophilisomes 
or lyophilisomes conjugated with a non-specific human IgG control antibody. As shown in 
figure 6, hKC4-conjugated lyophilisomes showed significant binding to OVCAR-3, SKOV-3, 
and HeLa cells compared to non-specific IgG-conjugated lyophilisomes. To confirm the 
findings of specific targeting to MUC1-overexpressing tumor cells, a competition 
experiment was carried out. Excess of free MUC1 antibody (10 µg/ml) was added to the 
cells 1 h prior to the incubation with antibody-conjugated lyophilisomes. Theoretically, 
MUC1 binding sites on the cell surface will be blocked by the excess of hKC4 antibody, 
resulting in control levels after incubation with hKC4-conjugated lyophilisomes. When 
SKOV-3 and HeLa cells were pre-incubated with an excess of hKC4 antibody, binding 
indeed decreased to baseline levels similar to controls and non-specific IgG-conjugated 
lyophilisomes (Fig. 6b and c). For OVCAR-3 cells, decreased binding was observed after 
pre-incubation with hKC4 antibody, but residual lyophilisome binding was above 
background levels (Fig. 6a). The high antigen expression (Table 2) of OVCAR-3 cells 
compared to other MUC1-positive cell lines and/or rapid re-expression of the antigen may 
be responsible for the binding being not fully blocked. The negative cell line, LS174T, did 
not show specific binding of lyophilisome preparations (Fig. 6d). Results were quantified 
using the percentage of cells associated with one or more lyophilisomes (Fig. 6e). OVCAR-3, 
Table 2  MUC1 expression of ovarian and cervix tumor cell lines
Cell line MUC1 expression Mean Fluorescence Intensity (N=3 ± SD)
OVCAR-3 +   805 ± 188
SKOV-3 +   232 ± 112
HeLa + 228 ± 56
LS174T -   5 ± 1
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SKOV-3, and HeLa cells all showed significantly more binding of hKC4-conjugated 
lyophilisomes, compared to non-specific IgG-lyophilisomes (75±7% vs. 9±2%; 61±4% vs. 
13±5%; 60±3% vs. 4±0%, respectively). For LS174T cells, increased binding was observed 
between IgG-conjugated lyophilisomes and hKC4-conjugated lyophilisomes. However, 
this was non-specific, as a pre-incubation with excess of hKC4 did not significantly 
decrease the binding of hKC4-conjugated lyophilisomes.
Figure 6  Cellular binding of various lyophilisome formulations to MUC1 overexpressing and 
MUC1 negative cancer cells. All cell lines were incubated either with hKC4-conjugated lyophilisomes, 
with and without a pre-incubation of excess hKC4 antibody, or non-specific IgG-conjugated 
lyophilisomes (control antibody). a-c) OVCAR-3, SKOV-3, and HeLa cells showed a significant shift to 
the right in the histogram, indicating increased binding of hKC4-conjugated lyophilisomes, whereas 
non-specific IgG-conjugated lyophilisomes showed background binding levels. Binding decreased 
to background levels after pre-incubation with hKC4 for SKOV-3 and HeLa cells. Binding to OVCAR-3 
cell did not completely decrease to the level of the control antibody. d) The negative cell line LS174T 
did not show specific binding for lyophilisome preparations.
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Binding of antibody-conjugated lyophilisomes in mixed cell culture
To investigate whether hKC4-conjugated lyophilisomes specifically target tumor cells that 
express MUC1 antigens, MUC1-positive cells were mixed with MUC1-negative cells in a 1:1 
ratio (Fig. 7). Positive (PHK26 stained) and negative cells (unstained) were analyzed in 
separate histograms. hKC4-conjugated lyophilisomes bound to cells that expressed MUC1 
antigen, whereas little binding was observed to LS174T cells. Non-specific IgG-conjugated 
lyophilisomes showed no preferential binding to either MUC1-positive or -negative cells. 
Confocal laser scanning microscopy confirmed these results. hKC4-conjugated lyophilisomes 
specifically targeted MUC-1-positive red cells compared to MUC-1 negative tumor cells 
(Fig. 7).
Cellular uptake of antibody-conjugated lyophilisomes
TEM was used to investigate the internalization of lyophilisomes. After a 1 h incubation of 
hKC4-conjugated lyophilisomes to OVCAR-3 cells, lyophilisomes bound to the cell membrane 
(Fig. 8a). However, after a 4 h incubation time, lyophilisomes were also internalized by 
Figure 6  Continued. e) Quantified results of a-d. *p<0.05 **p<0.001.
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Figure 7  Specific targeting of cancer cells in a combination culture of MUC1 positive and negative 
cells. MUC1 positive and negative cells were mixed in a 1:1 ratio. To distinguish between both cell 
types, MUC1 positive cells were stained red by PKH26 membrane dye. For evaluation, positive and 
negative cells were plotted in separate histograms. a-c) OVCAR-3 (a), SKOV-3 (b), and HeLa (c) cells 
showed binding of hKC4 conjugated lyophilisomes when compared to LS174T cells. The non-specific 
IgG-conjugated lyophilisomes did not show a preferential binding to either cell type. Confocal laser 
scanning microscopy confirmed these results, where MUC1 positive cells could be distinguished 
from negative cells by their red fluorescence. hKC4-conjugated lyophilisomes showed specific 
targeting to MUC1 positive red cells (arrows) in contrast to MUC1 negative cells. Scale bar represents 
60 µm.
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the tumor cells (Fig. 8b). The same phenomenon was observed for SKOV-3 and HeLa cells 
(results not shown). For non-specific IgG-conjugated lyophilisomes, almost no binding 
was observed and lyophilisomes were not taken up by the cell (Fig. 8c).  The cell membrane 
of OVCAR-3 cells was rather undisturbed after incubation with IgG-conjugated lyophilisomes. 
However, hKC4-conjugated lyophilisomes triggered membrane ruffling, most likely to 
internalize attached hKC4-conjugated lyophilisomes (Fig. 8b).
Figure 8  Cellular uptake of lyophilisomes as analyzed by transmission electron microscopy. 
OVCAR-3 cells were incubated with both hKC4-conjugated (a and b) and non-specific IgG-conjugated 
(c) lyophilisomes for one (a) and four (b and c) hours. a) hKC4-conjugated lyophilisomes bound 
to OVCAR-3 cells after one hour incubation. b) After an incubation time of four hours, internalized 
hKC-4-conjugated lyophilisomes were observed in OVCAR-3 tumor cells. c) No uptake was observed 
using non-specific IgG-conjugated lyophilisomes after a 4 h incubation.
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DISCUSSION
A major goal in cancer research is to achieve high drug levels in target cells, without 
affecting healthy cells. Drug delivery systems have the advantage of guiding drugs to the 
tumor tissue, as they protect the drug until it reaches the target site. In order to achieve 
higher drug levels in the target cells, drug delivery systems can be designed with ligands or 
antibodies for active targeting [32,33]. In this study, we designed a MUC1 lyophilisome- 
based targeted delivery system to enhance binding in MUC1 overexpressing tumor cells.
Current nano/micro drug delivery systems for cancer therapeutic applications include 
liposomes, dendrimers, micelles, nanoconjugates, and (protein-based) nanoparticles 
[2,34,35]. Among the available drug carrier systems, protein-based nanoparticles are 
particularly interesting as they hold certain advantages such as increased stability during 
storage, non-toxicity, biocompatibility, and biodegradability in vivo [36,37]. Lyophilisomes 
can be prepared from a large variety of water-soluble macromolecules including proteins 
(e.g. albumin and elastin). In fact, virtually any biomolecule can be incorporated into the 
wall/lumen of the capsule, resulting in a highly flexible carrier system with multiple 
applications. Recently we showed that lyophilisomes have been efficiently loaded with 
doxorubicin resulting in tumor cell elimination in vitro [6].
In order to use lyophilisomes for active targeting of tumor cells, a MUC1-reactive hKC4 
antibody was conjugated to lyophilisomes. First, maleimide groups were introduced on 
lyophilisomes whereas sulfhydryl groups were created on the antibody. In lyophilisomes, 
primary amine groups in albumin have already been partially used for stabilization of the 
capsules, but a 2 h vapor fixation left sufficient amines for conjugation. For the antibody, 
one to two thiol groups would be ideal for conjugation, since it ensures an efficient 
reaction while preserving the immunoreactivity of the antibody [17]. When introducing 
thiol groups, long incubations come with the risk of dimerization of sulfhydryl groups 
[11,17]. Similar to other studies, our results indicate that incubations longer than 5 h are 
therefore not optimal. Antibody conjugation to lyophilisomes proved to be reproducible 
when using a 5 h incubation with a 50-fold molar excess of Traut’s reagent at pH 7.2. 
Antibody conjugation did not influence the mean particle diameter, as demonstrated by 
DLS and qNano and the complex was stable and functional for at least three months 
when stored at 4°C (data not shown). 
In this study, a MUC1 antibody (hKC4) was conjugated to lyophilisomes to actively 
target tumor cells. Mucins are expressed by various epithelial cell types and have a 
central role in maintaining homeostasis and, therefore, promoting cell survival [38]. 
These characteristics also contribute to tumor cell survival when expressing mucins on 
their cellular membrane. Mucins are also able to bind growth factors to further stimulate 
the proliferation of tumor cells [38]. Since many tumors show high expression of MUC1, 
whereas it is expressed to a limited extent in normal cells, it is a good candidate to 
specifically target cancer cells [38].
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When studying specificity of tumor cell targeting in vitro, hKC4-conjugated lyophili -somes 
showed an increased tumor targeting specificity. The relative fluorescent values obtained 
by FACS for the single cell experiments are in good correspondence with other MUC1 
targeting drug delivery systems studies [10,11,39]. Dinauer et al. described their results by 
absolute gain in specific targeting [10]. Their group achieved a 16-fold gain in specific 
targeting compared to IgG-nanoparticles. Our findings showed a 15- fold, 8-fold, and 
5-fold gain for respectively HeLa, OVCAR-3, and SKOV-3 cells. IgG-conjugated lyophilisomes 
showed an average background around 9%, compared to 6% measured by Dinauer et al. 
Furthermore, Steinhauser et al. showed that cellular association can be time dependent 
[11]. In our study, an incubation time of only 1 h was used whereas other studies incubated 
for a longer period of time up to 4 h, emphasizing on the rapid binding of hKC4-conjugat-
ed lyophilisomes to MUC1 overexpressing tumor cells [10,17,40]. Furthermore, the 
incubation method (static vs. dynamic) is likely of importance. In this study, lyophilisomes 
were incubated with tumor cells under dynamic conditions, whereas other studies used 
static incubation conditions [17,40]. Even under dynamic conditions, hKC4-conjugated 
lyophilisomes specifically bound to MUC1-overexpressing tumor cells. 
hKC4-conjugated lyophilisomes showed specific binding and uptake by MUC1- 
overexpressing tumor cells. To demonstrate the specificity of antibody-conjugated 
lyophilisomes, MUC1 positive and negative cells were mixed in culture. In this study, 
hKC4-conjugated lyophilisomes specifically bound to MUC1-overexpressing cells, whereas 
they did not bind to MUC1-negative LS174T cells. This observation held for all MUC1-positive 
cell lines used in this study (OVCAR-3, SKOV-3 and HeLa cells).
When examining the uptake, lyophilisomes specifically bound to MUC1-overexpressing 
tumor cells due to their specific antibody – antigen interaction. After binding, TEM results 
indicated the internalization of lyophilisomes modified with hKC4. Cells have a variety of 
endocytic mechanisms, including phagocytosis and pinocytosis, where pinocytosis occurs 
by at least four basic mechanisms (macropinocytosis, clathrin-mediated endocytosis, caveo-
lae-mediated endocytosis, and clathrin- and caveolae-independent endocytosis) [41,42]. 
Phagocytosis and macropinocytosis (0.5 – 3 µm) are mechanisms for uptake of large 
particles whereas most mechanisms of pinocytosis internalize small particles (<200 nm) 
[42–44]. TEM images strongly suggest that lyophilisomes are internalized by phagocytosis 
or macropinocytosis, since intensive ruffling of the cell membrane was observed to the 
outside embracing the lyophilisome. In addition, the particle size of lyophilisomes ranges 
between 100 up to 3,000 nm, supporting uptake via phagocytosis or macropinocytosis 
[6,43]. However, lyophilisomes smaller than 200 nm could still be internalized by one of the 
other mechanisms of pinocytosis.
As demonstrated previously, lyophilisomes can be loaded with anti-tumor drugs, e.g. 
doxorubicin and curcumin [6]. In order to use antibody-modified lyophilisomes for the 
treatment of cancer, active tumor targeting can be combined with the drug delivery properties 
of lyophilisomes to establish a powerful system to selectively eliminate tumor cells.
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CONCLUSION
Albumin-based lyophilisomes were functionalized with anti-MUC1 antibodies to obtain a 
selective drug carrier system specific towards cancers overexpressing MUC1. The 
lyophilisomes prepared specifically targeted MUC1 expressing tumor cell lines and were 
internalized. Functionalized lyophilisomes may present a novel strategy for the specific 
delivery of anti-tumor drugs to cancer cells. 
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ABSTRACT
Lyophilisomes are a novel class of biodegradable proteinaceous nano/micrometer capsules 
with potential use as drug delivery carrier. Cell-penetrating peptides (CPPs) including the 
TAT peptide have been successfully implemented for intracellular delivery of a broad 
variety of cargos including various nanoparticulate pharmaceutical carriers. In the present 
study, lyophilisomes were modified using CPPs in order to achieve enhanced cellular 
uptake. Lyophilisomes were prepared by a freezing, annealing, and lyophilization method 
and a cystein-elongated TAT peptide was conjugated to the lyophilisomes using a hetero-
bifunctional linker. Fluorescent-activated cell sorting (FACS) was utilized to acquire a 
lyophilisome population with a particle diameter smaller than 1,000 nm. Cultured HeLa, 
OVCAR-3, Caco-2 and SKOV-3 cells were exposed to unmodified lyophilisomes and 
TAT-conjugated lyophilisomes and examined with FACS. HeLa cells were investigated in 
more detail using a trypan blue quenching assay, confocal microscopy, and transmission 
electron microscopy. TAT-conjugation strongly increased binding and cellular uptake of 
lyophilisomes in a time-dependent manner in vitro, as assessed by FACS. These results 
were confirmed by confocal microscopy. Transmission electron microscopy indicated 
rapid cellular uptake of TAT-conjugated lyophilisomes via phagocytosis and/or macro-
pinocytosis. In conclusion, TAT-peptides conjugated to albumin-based lyophilisomes are 
able to enhance cellular uptake of lyophilisomes in HeLa cells.
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INTRODUCTION
An innovative strategy in cancer therapy utilizes drug delivery carriers to increase the 
therapeutic effect of anti-tumor drugs. The role of drug delivery carriers in this context is 
to improve pharmacokinetics and dynamics by protecting the drug from degradation 
[1–3]. Contemporary drug delivery systems include nanoparticulate systems loaded with 
anti-tumor drug and conjugates directly coupled to the drug. The unique property of 
nanoparticle carriers is their ability to encapsulate and deliver a high dose of anti-tumor 
drugs, including poorly soluble drugs, and to exploit the enhanced permeability and 
retention (EPR) effect for tumor targeting [4]. Because of these favorable characteristics, there 
has been intense interest in the development of nanoparticulate drug delivery systems.
Nanoparticles currently investigated for cancer therapeutic applications include 
liposomes, polymersomes, dendrimers, micelles, carbon nanotubes, nanoconjugates and 
(protein-based) nanospheres or capsules [5–7]. Among the available potential drug carrier 
systems, protein-based nanoparticles are particularly interesting as they hold certain 
advantages such as good stability during storage, non-toxicity, biocompatibility, and bio-
degradability in vivo[8,9]. Recently we showed that lyophilisomes, a novel class of 
proteinaceous biodegradable hollow nano/micrometer capsules, show potential as a 
drug delivery capsule [10,11]. Lyophilisomes can be prepared from a large variety of 
water-soluble macromolecules including proteins (e.g. albumin and elastin) but also poly-
saccharides (e.g. heparin). In fact, virtually any biomolecule can be incorporated into the 
wall/lumen of the capsule, resulting in a highly flexible carrier system with multiple 
applications. We previously demonstrated that enzymes introduced in the capsule’s wall and 
in the lumen are bioactive and able to convert a substrate [10]. Furthermore, lyophilisomes 
have been efficiently loaded with doxorubicin resulting in tumor cell elimination in vitro 
[11]. In order to obtain a selective drug delivery system, lyophilisomes have also been 
modified with antibodies, resulting in specific targeting of the cell of interest in vitro [12]. 
Due to these properties, lyophilisomes can be deployed for the design of multifunctional 
targeting systems. 
Lyophilisomes were prepared from albumin. Albumin is an attractive macromolecular 
carrier that has been shown to be non-toxic, non-immunogenic, biodegradable to produce 
innocuous degradation products, and easy to purify [13]. It is thus a suitable candidate for 
nanoparticle preparation, as demonstrated by FDA-approved products such as Abraxane 
[14,15] and Albunex [16,17].
Since delivery of nanocarriers is generally based on passive accumulation in pathological 
tissues, they do not efficiently deliver their cargo to specific cells. When drug delivery 
carriers arrive at the tumor site, they have to cross the plasma membrane in order to deliver 
the drug into the cell. The plasma membrane, however, prevent proteins, peptides, and 
nanoparticulate drug carriers from entering the cell in the absence of an active transport 
mechanism [18]. Cell-penetrating peptides (CPPs) have been successfully used to deliver a 
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large variety of cargos to the cell interior including proteins [19], peptides [20], nucleic acids 
[21] and pharmaceutical nanocarriers [22–24]. CPPs are short peptides consisting of up to 
30 amino acids that are able to translocate across the cellular membrane [25]. When CPPs 
are conjugated to drug delivery carriers, efficient cellular uptake of the carriers can be 
achieved [26]. A representative CPP is the TAT peptide, derived from the TAT protein 
(trans-activation transcriptional activator) of the human immunodeficiency virus type 1 
(HIV-1) [27,28]. The TAT peptide consists of 11 amino acids with the sequence YGRKKRRQRRR. 
The abundance of lysine and arginine residues makes it highly positively charged, 
important for the interaction with the plasma membrane. In this study, the TAT peptide 
was conjugated to lyophilisomes to investigate whether CPPs are able to enhance cellular 
uptake of lyophilisomes. 
MATERIALS & METHODS
Materials
Bovine serum albumin was purchased from PAA Laboratories (Linz, Austria). FITC-conjugated 
bovine albumin was purchased from Sigma Aldrich (Steinheim, Germany). Sulfo-GMBS 
(sulfo-N-[γ-maleimidobutyryloxy]sulfosuccinimide ester) was purchased from Pierce 
Biotechnology (Rockford, IL, USA). Glutaraldehyde and formaldehyde were obtained from 
Merck (Darmstadt, Germany). Cysteine functionalized TAT peptide (C-Ahx-YGRKKRRQRRR) 
was purchased from EMC Microcollections GmbH (Tübingen, Germany), in which Ahx = 
aminohexanoic acid linker.
Methods
Preparation of lyophilisomes
Lyophilisomes were prepared from albumin as described previously [11]. Briefly, droplets 
of a solution of 0.25% (w/v) bovine serum albumin (BSA) in 0.01 M acetic acid were frozen 
in liquid nitrogen (-196°C). The frozen albumin preparation was incubated at -10 to -20°C 
for 3 h (annealing step), and subsequently lyophilized. This procedure results in hollow 
nano/micro spheres (“lyophilisomes”). In order to visualize the lyophilisomes, FITC- 
conjugated albumin was added to non-labeled albumin (1:10) in the starting solution. 
To obtain stabilized lyophilisomes, they were vapor crosslinked with glutaraldehyde and 
formaldehyde. Generally we prepare 40 ml of a 0.25 % BSA solution, which corresponds to 
100 mg albumin (2.5 mg/ml). The final lyophilisome population was centrifuged three or 
four times at low speed (60x g; Thermo, Heraeus Fresco 17; Newport Pagnell, Great Britain) 
to remove large lyophilisomes and sheet-like structures, until no pellet was observed. 
After this procedure, about 30% of the original weight of lyophilisomes remained. 
Lyophilisomes (1 mg/ml) were stored in 0.1% (v/v) Tween-20 (Sigma Aldrich, Steinheim, 
Germany) in phosphate buffered saline (PBS-T, pH 7.4).
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Conjugation of cell-penetrating peptide to lyophilisomes
A schematic representation of the conjugation reactions is depicted in figure 1.
Reaction 1: Activation of lyophilisomes. To obtain maleimide-activated lyophilisomes, 
1 mg lyophilisomes were resuspended in 1 ml PBS-T and incubated overnight with 31 µl 
of 10 mM sulfo-GMBS in PBS-T (pH 8.0) at 4°C on a rotator (36 rpm, “Assistant” Rotating 
mixer, Karl Hecht, Sondheim, Germany), resulting in a 20:1 molar ratio of sulfo-GMBS:albu-
min. Excess sulfo-GMBS was removed by centrifugation (5 min, 17,000x g, 4°C) with three 
washing steps in PBS-T (pH 6.5).
Reaction 2: Conjugation of TAT peptide to lyophilisomes. For the coupling reaction, 1 ml of 
1 mg/ml sulfhydryl-reactive lyophilisomes in 0.1% PBS-T was centrifuged and conjugated in 
1 ml of cysteine functionalized TAT peptide (100 µM; C-Ahx-YGRKKRRQRRR) in 0.1% PBS-T 
(pH 6.5). Non-coupled TAT peptides were removed by centrifugation, using three washing 
steps in 0.1% PBS-T (pH 7.4). TAT-conjugated lyophilisomes were stored at 4°C in the dark. 
Sorting of lyophilisomes by fluorescence-activated cell sorting
Fluorescence-activated cell sorting (FACS) was applied to select for small lyophilisomes 
(<1,000 nm) using a Coulter Epics Elite flow cytometer (BeckmanCoulter, Miami, FL, USA). 
Only small FITC-positive lyophilisomes were sorted (for settings, see figure 3). To achieve 
high sensitivity, gain was set at 20.
Particle size measurements by qNano
The qNano (Izon, Science Ltd., Burnside, New Zealand) was used to measure particle size 
distribution of lyophilisomes [11,29]. To ensure a continuous flow of particles, a pore size of 
600 – 2,000 nm was used. Data were analyzed with Izon Control Suite 2.1 software. 
Cell culture
HeLa (ACC 57, DSMZ, Braunschweig, Germany) and OVCAR-3 (#HTB-161, ATCC, LGC 
Standards GmbH, Wesel, Germany) cells were cultured in RPMI 1640 GlutaMAX medium 
Gibco (Karlsruhe, Germany) supplemented with 10% (v/v) fetal calf serum (FCS; PAA 
Laboratories, Pasching, Austria). Caco-2 cells (#HTB-37, ATCC) and SKOV-3 cells (#HTB-77, 
ATCC) were cultured in DMEM 1640 GlutaMAX medium Gibco supplemented with 20% 
(v/v) and 10% (v/v/) fetal calf serum, respectively. Cells were cultured in a humidified 
atmosphere with 5% CO
2
 at 37°C. Subconfluent cells were dissociated with 0.05% trypsin 
(w/v) in 0.02% ethylenediaminetetraacetic acid (EDTA) (w/v) in PBS (PAA Laboratories) and 
were maintained as proliferating cultures.
For FACS, cells were stained with the plasma membrane dye PKH26 (Sigma Aldrich, 
Missouri, USA) [30,31]. One million cells were incubated in 2 µM PKH26 dye in 500 µl buffer 
(according to manufacturer’s protocol) for 5 min. To stop the staining reaction, 500 µl FCS 
was added and incubated for 5 min. Subsequently, cells were washed three times with 
culture medium.
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Cellular binding and internalization of lyophilisomes with and without TAT peptide
To determine whether the TAT peptide can promote the binding and internalization of 
lyophilisomes with HeLa, OVCAR-3, Caco-2 and SKOV-3 cells were seeded in a 24-well plate 
(30,000 cells/well in 1 ml medium). Cells were left to adhere overnight and subsequently 
incubated for 1 h with unsorted lyophilisomes with and without TAT peptide conjugated 
to them (25 µg/ml). After incubation, cells were washed three times with PBS to remove 
unbound lyophilisomes and harvested with enzyme-free EDTA solution (PAA Laboratories). 
Finally, cells were resuspended in 0.2% BSA in PBS and analyzed by FACS (FACSCalibur 
Becton Dickinson, Breda, Netherlands). Using the appropriate positive and negative 
controls FACS settings were adjusted. When lyophilisomes did not bind to cells, 
lyophilisomes were depicted at a fluorescent signal of 101 or below and cells were regarded 
negative. When lyophilisomes did bind to cells, they showed a fluorescent signal higher 
than 101. Data were analyzed by FlowJo software (Version 9.4, Treestar, Ashland, OR, USA).
Internalization studies of lyophilisomes by cells
FACS
In order to discriminate between attached and internalized lyophilisomes, a FITC 
quenching trypan blue assay was used [32–34]. Quenching of FITC signal occurs because 
trypan blue absorbs the light emitted by FITC-labeled lyophilisomes after excitation. The 
FITC signal of internalized lyophilisomes however, is not quenched since trypan blue 
cannot pass the plasma membrane. The fluorescence remaining after trypan blue quenching 
must therefore result from internalized lyophilisomes, as only extracellular fluorescence of 
FITC-lyophilisomes is quenched.
To investigate the cellular uptake of lyophilisomes, PKH26 stained HeLa cells were seeded 
in a 24-well plate (30,000 cells/well) and left to adhere overnight. Cells were incubated with 
500,000 FACS-sorted lyophilisomes with and without TAT peptide for 1 and 4 h. After 
incubation, cells were washed three times with 0.2% (w/v) BSA in PBS, dissociated with 
enzyme-free EDTA dissociation buffer, resuspended in 1 ml culture medium and transferred 
to an eppendorf tube. Subsequently, cells were washed three times with 0.2% BSA-PBS 
by centrifugation (3 min, room temperature, 100x g) and incubated with 0.5% (w/v) trypan 
blue for 10 min and washed three times with 0.2% BSA-PBS. Cells were analyzed by 
FACSCalibur flowcytometry. Data were analyzed by FlowJo Software. 
Confocal microscopy
To visualize cellular uptake of lyophilisomes, confocal microscopy was performed on living 
cells. HeLa cells were seeded in an 8-well microscopy chamber (Nunc; 30,000 cells/well) 
and left to adhere overnight. Cells were incubated with sorted lyophilisomes with and 
without TAT peptide using 0.8 and 3.5 million lyophilisomes in 200 µl per sample for 4 h in 
RPMI medium containing 10% FCS at 37°C. As a control, medium without lyophilisomes 
was used. After incubation, cells were washed three times, incubated for 5 min with 
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CellMask Orange (5 µg/ml) to visualize the plasma membranes and then washed again, all 
with the same medium. Cells were kept at 37°C on a temperature controlled microscope 
stage and living cells were imaged immediately with a Leica SP5 confocal microscope 
(Leica Microsystems, Mannheim, Germany). FITC was excited at 488 nm and emission was 
collected between 500-550 nm. CellMask orange was excited at 561 nm and emission was 
collected between 570-650 nm. Images were recorded sequentially using Leica Application 
Suite Software (Advanced Fluorescence Lite, 2.3.0. build 5131).
Transmission electron microscopy
Cells incubated with lyophilisomes with and without TAT peptide as described in the 
Materials and Methods section ‘FACS’ were embedded in 1.5% (w/v) agarose, fixed in 2% 
(v/v) glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), post-fixed with 1% (w/v) osmium 
tetroxide, dehydrated in an ascending series of ethanol, and embedded in Epon 812. 
Ultrathin sections (60 nm) were cut and picked up on Formvar-coated grids, post-stained 
with lead citrate and uranyl acetate, and examined with a JEOL 1010 transmission electron 
microscope (Tokyo, Japan).
Statistical Analysis
Data are presented as mean with standard deviation. Data of Results section ‘Cellular 
binding and internalization of lyophilisomes with and without TAT peptide’ were analyzed 
using two-tailed Student’s t-tests. Data of Results section ‘Trypan blue assay and FACS’ were 
analyzed using two-way Anova Bonferroni post-hoc tests. All statistical analyses were 
performed in Graphpad Prism 5.0 (Graphpad, San Diego, CA, USA). P values <0.05 were 
considered significant.
RESULTS
Conjugation of TAT peptide to lyophilisomes
To probe the possibility of using CPP for enhanced intracellular delivery, lyophilisomes 
were modified with a cysteine-functionalized TAT peptide using the heterobifunctional 
linker sulfo-GMBS (Fig. 1). The succinimidyl ester functionality is conjugated to primary 
amine groups on the lyophilisome while the maleimide functionality is used for conjugation 
to the free thiol of the cysteine residue coupled to the TAT peptide. 
Cellular binding and internalization of lyophilisomes with and without 
TAT peptide
To address the presence of the TAT peptide on TAT-conjugated lyophilisomes, unmodified 
lyophilisomes and TAT-conjugated lyophilisomes were administered to HeLa, OVCAR-3, 
Caco-2 and OVCAR-3 cells. Using standard FACS as a functional assay, it is not possible to 
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discriminate between cellular attachment and internalization. Instead, the total of cell 
binding and internalization is measured (Fig. 2). For HeLa cells, TAT-conjugated lyophilisomes 
showed an about 8-fold increase in lyophilisome-positive cells compared to lyophilisomes 
without the TAT peptide (86±3% and 12±4% lyophilisome-positive cells for TAT-conjugated 
and unmodified lyophilisomes, respectively. OVCAR-3 and Caco-2 cells showed about a 
5-fold increase in lyophilisome-positive cells compared to lyophilisomes without the TAT 
peptide (lyophilisome-positive cells: 97±3% and 19±3% for OVCAR-3; 87±3% and 16±8% 
for Caco-2) for TAT-conjugated and unmodified lyophilisomes, respectively. SKOV-3 cells 
gave a high background value when incubated with lyophilisomes without TAT (67±20%), 
but still showed a 1.6 fold statistically significant increase with the presence of TAT peptide 
(95±10%).
Lyophilisomes sorted by fluorescence-activated cell sorting
When using lyophilisomes for tumor targeting, lyophilisomal size is an important 
parameter. The initial lyophilisome population included sizes up to 2.8 µm (Fig. 3a). To 
obtain a more monodisperse capsule population, lyophilisomes were sorted by FACS. 
Lyophilisomes were separated based on forward scatter and FITC fluorescence (FL1 
channel; Fig. 3c). To verify the procedure, a rerun of sorted lyophilisomes was performed 
(Fig. 3d). Using this methodology, larger lyophilisomes as well as sheet-like structures 
(confirmed by scanning electron microscope) were separated from small lyophilisomes. 
These results were substantiated by qNano size analysis using a lyophilisome preparation 
before (Fig. 3a) and after (Fig. 3b) sorting (approximately 90% below 1 µm). Measurements 
using the qNano consisted of 200 – 250 particles. The size distribution contained multiple 
Figure 1  Schematic illustration of the conjugation of the cell-penetrating peptide (CPP) TAT to 
lyophilisomes. (1) Primary amine groups of lyophilisomes react with Sulfo-GMBS introducing reactive 
maleimide groups. (2) CPPs (cysteine-functionalized TAT-peptides; C-Ahx-YGRKKRRQRRR) are 
conjugated to maleimide-conjugated lyophilisomes, resulting in stable CPP-conjugated lyophilisomes. 
Sulfo-GMBS = sulfo-N-[γ-maleimidobutyryloxy]sulfo succinimide ester; Ahx = aminohexanoic acid; 
TAT = trans-activating transcriptional activator.
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peaks that can be explained by the low number of particles. Due to the limitations of the 
qNano instrument particles smaller than 600 nm could not be reliably detected which 
overestimates the average size of the lyophilisomes. Pilot experiments with a smaller 
qNano pore (200 – 800 nm) revealed the presence of lyophilisomes below 600 nm (results 
not shown), but larger lyophilisomes in the preparation frequently blocked this pore.
Cellular uptake of TAT-conjugated lyophilisomes
Trypan blue assay and FACS
To determine the internalization efficiency of sorted lyophilisomes with and without TAT 
peptide, a trypan blue quenching assay was used in order to distinguish between 
internalized and non-internalized (but plasma membrane-associated) lyophilisomes. This 
assay is based on the quenching of fluorescence of FITC-labeled lyophilisomes by the vital 
stain trypan blue (which does not penetrate plasma membranes). To validate that trypan 
blue also quenches fluorescence of FITC labeled lyophilisomes, lyophilisomes were 
incubated with trypan blue in the absence of cells and evaluated by FACS (Fig. 4). 
Figure 2  Cellular binding and internalization of unmodified lyophilisomes and TAT-conjugated 
lyophilisomes. HeLa, OVCAR-3, Caco-2 and SKOV-3 cells incubated with TAT-conjugated and 
unmodified lyophilisomes resulted in 86±3% and 12±4%, 87±3% and 16±8%, 97±3% and 19±3%, 
and 95±10% and 67±20% lyophilisome-positive cells, respectively.
TAT = trans-activating transcriptional activator. *p<0.01 ***p<0.0001.
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Lyophilisomes that were not incubated with trypan blue showed a mean fluorescence 
intensity of 1,339±252. Lyophilisomes incubated in a 0.5% trypan blue solution gave a 
mean fluorescent intensity of 85±31, corresponding to a quenching efficacy of 94±2% 
(Fig. 4b). After one, two and three washings after the trypan blue incubation, the measured 
mean fluorescence was 161±25, 176±22, and 192±19 or 88±1%, 87±1% and 85±1% 
quenching efficacy, respectively. This indicates that trypan blue was not easily washed out 
of the lyophilisomes and fluorescence remained quenched. This is important as three 
washings steps were used prior to FACS analysis.
Figure 3  Sorting of lyophilisomes by fluorescence-activated cell sorting. a and b) A representative 
size distribution of the initial lyophilisome population (a) and sorted lyophilisomes (b) is depicted, 
showing smaller lyophilisomes after sorting. Note the difference in x and y axes. c) Initial lyophilisome 
population depicted in a FACS dot plot with forward (size) / FITC-positive lyophilisome (FL1 channel) 
scatter where gated FITC-positive lyophilisomes were sorted. d) After sorting, the scatter showed 
merely small lyophilisomes, as large lyophilisomes were removed.
81
ENHANCED CELLULAR UPTAKE OF LYOPHILISOMES
4To investigate whether TAT peptides can enhance internalization of sorted lyophilisomes, 
the trypan blue quenching assay was performed in the presence of HeLa cells (Fig. 5). 
Cells were incubated with 500,000 sorted lyophilisomes with and without TAT peptide. 
Incubation for 1 h with TAT-conjugated lyophilisomes resulted in many lyophilisome- 
positive cells (67±3%) and moderate cellular uptake (25%±1). In contrast, unmodified 
lyophilisomes showed few lyophilisome-positive cells (6±5%) and almost no internalization 
(1±1%). Interestingly, when lyophilisomes were incubated for 4 h, the number of lyophili-
some-positive cells of TAT-conjugated lyophilisomes remained high (79±8%) and cellular 
uptake strongly increased (59±14%), whereas unmodified lyophilisomes still showed a 
moderate number of lyophilisome-positive cells (17±8%) and little internalization (7±2%).
Confocal microscopy
Internalization of TAT-conjugated lyophilisomes in HeLa cells was visualized by confocal 
microscopy (Fig. 6). After 4 h of incubation, TAT-conjugated lyophilisomes showed 
extensive uptake for both low (0.8 million / 200 µl) and high (3.5 million / 200 µl) numbers 
of lyophilisomes (Fig. 6c and g). Almost no internalization was observed when HeLa cells 
were incubated with unmodified lyophilisomes (Fig. 6a and e). The corresponding bright 
field images showed that lyophilisomes did not lead to detectable morphological changes 
of the cells (Fig. 6b, d, f and h).
Transmission electron microscopy
In order to investigate the binding and uptake of TAT-conjugated lyophilisomes in HeLa 
cells in detail, TEM was used (Fig. 7). When unmodified lyophilisomes were added to HeLa 
Figure 4  Quenching of FITC fluorescent lyophilisomes by trypan blue in the absence of cells. 
Results show decreased fluorescence (a) and efficient quenching (b) up to three washings steps of 
FITC fluorescent lyophilisomes by trypan blue.
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cells, no binding or uptake was observed and the plasma membrane appeared largely 
unruffled (Fig. 7a). However, when TAT-conjugated lyophilisomes were added, multiple 
stages of internalization could be distinguished, including attachment and internalization 
(Fig. 7b and c). Initially, TAT-conjugated lyophilisomes bound to HeLa cells and initiated 
membrane ruffling (Fig. 7b). Subsequently, capsules were internalized (Fig. 7c). Furthermore, 
initial signs of degradation of lyophilisomes could be observed, as degradation products 
were visible (black arrows; Fig. 7d). 
Figure 5  Internalization of lyophilisomes with and without TAT peptide into HeLa cells. FACS 
showed a large number of lyophilisome-positive cells for TAT-conjugated lyophilisomes after 1 h 
(67±3%) without trypan blue and a cellular uptake of 25±1% with trypan blue. Values for lyophilisomes 
without TAT peptide were low. When lyophilisomes were incubated for 4 h, TAT-conjugated 
lyophilisomes conserved the large number of lyophilisome-positive cells (79±8%) with an increased 
internalization of 59±14%, while unmodified lyophilisomes still showed few lyophilisome-positive 
cells and little cellular uptake. *p<0.01 **p<0.001. 
CPP = cell penetrating peptide; TAT = trans-activating transcriptional activator.
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Figure 6  Internalization of lyophilisomes without and with TAT peptide by HeLa cells. Lyophilisomes 
without and with TAT peptide were administered to 30,000 HeLa cells using two dosages (0.8 million 
/ 500 µl (a-d) and 3.5 million / 500 µl (e-h). Cells incubated with lyophilisomes without TAT peptide 
had internalized few lyophilisomes (a and e), whereas TAT-conjugated lyophilisomes showed high 
cellular uptake for almost all cells (c and g). Green fluorescence corresponds to lyophilisomes and 
red fluorescence (CellMask orange) visualizes the plasma membrane. Bright field images (b, d, f and 
h) show normal morphology of the cells. Scale bar represents 20 µm.
TAT = trans-activating transcriptional activator.
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DISCUSSION
Our laboratory previously demonstrated that lyophilisomes show potential as a drug 
delivery system [11,12]. To further optimize these biocapsules, we studied the effect of 
TAT-functionalization on the in vitro internalization of lyophilisomes. Intracellular delivery 
Figure 7  Cellular uptake of TAT-conjugated lyophilisomes as analyzed by transmission electron 
microscopy. HeLa cells were incubated with unmodified (a) and TAT-conjugated lyophilisomes (b-d) 
for 4 h. a) No attachment or uptake was observed using unmodified lyophilisomes. b-d) TAT- 
conjugated lyophilisomes (white arrows) showed various processes required for effective drug 
delivery systems, such as attachment (b) and uptake (c). Additionally, signs of degradation of the 
capsule inside the cell were visualized (black arrows, d). Scale bar represents 1.0 µm.
TAT = trans-activating transcriptional activator.
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of therapeutic molecules is one of the key problems in drug delivery. Many pharmaceutical 
compounds have to be delivered intracellularly to exert their therapeutic action [22]. 
CPPs have been shown to act as a powerful transport vector for inducing the cellular 
uptake of a large variety of cargos [18].  At present, pharmaceutical nanocarriers are much 
in focus for their capacity to increase the stability of administered drugs, improve their 
concentration at their site-of-action and decrease undesired side effects. Various studies 
report increased uptake and specific delivery to intracellular organelles when conjugating 
CPPs to drug delivery systems, thereby increasing the efficiency of nanocarriers as drug 
delivery systems [35–37].  
As previously reported, lyophilisomes range in size from 100 up to 3,000 nm in diameter 
[11]. In this study, we demonstrated that using FACS, small lyophilisomes could be sorted 
out of the initial population, narrowing the size distribution. 
In the present study, FACS was used to investigate the total cell binding and inter nalization of 
(TAT-conjugated) lyophilisomes in HeLa, OVCAR-3, Caco-2, and SKOV-3 cells. To investigate 
the cellular uptake and subcellular distribution of (TAT-conjugated) lyophilisomes in HeLa 
cells in more detail, confocal microscopy, and TEM were utilized. FACS demonstrated a 
high number of lyophilisome-positive cells when incubated with TAT-conjugated 
lyophilisomes compared to unmodified lyophilisomes. This may be explained by 
interaction of the TAT peptide with negatively charged sulfated glycans at the cell surface, 
such as heparan sulphate [38,39]. Only SKOV-3 cells showed a high background when 
incubated with unmodified lyophilisomes, which has been shown for other drug carriers 
added to this cell line [40].
To discriminate between internalization and attachment, a trypan blue quenching assay 
was applied on HeLa cells incubated with lyophilisomes. This assay showed that cellular 
uptake was enhanced when TAT peptides were conjugated to lyophilisomes. The degree 
of internalization may even have been underestimated as our capsules are likely to enter 
the acidic lysosomes in the cell [41] and since FITC fluorescein is virtually non-fluorescent 
below pH 5 [42]. The trypan blue assay also demonstrated that cellular uptake of 
TAT-conjugated lyophilisomes increased over time. After 1 h, 25±1% of the cells internalized 
TAT-conjugated lyophilisomes, whereas 59±14% of cells had done so after an incubation 
period of 4 h. We most likely added too little lyophilisomes in the trypan blue internaliza-
tion study to achieve lyophilisome internalization of all available cells. This is supported by 
confocal microscopy, which revealed that almost all cells internalized at least one 
lyophilisome when administering more lyophilisomes. TEM images showed different 
stages of cellular uptake (attachment and internalization) of TAT-conjugated lyophilisomes. 
The results strongly suggest that TAT-conjugated lyophilisomes are internalized by 
phagocytosis and/or macropinocytosis, as intensive plasma membrane ruffling was 
observed during uptake. This suggestion would be in line with the particle size of 
lyophilisomes [43]. However, lyophilisomes smaller than 200 nm, could still be internalized 
by one of the mechanisms of endocytosis.
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If we compare our findings to other studies, the increased internalization efficiency 
compared to unmodified particles is within the range of reported values for TAT peptides 
conjugated to cargos such as liposomes [44,45]. However, it is difficult to compare inter-
nalization for different kinds of nanoparticles, since different cell types and different 
amounts and sizes of nanoparticles are used for in vitro experiments, e.g. the larger the 
particle the more time it takes to establish internalization [46]. 
The ability of CPPs to enhance cellular uptake non-specifically and receptor- independently 
provides the opportunity to target diverse cell types with a variety of carriers. In literature, 
it has been observed that next to HeLa, OVCAR-3, Caco-2 and SKOV-3 cells, the TAT peptide 
can enter other tumor cells, for instance bladder cancer (HTB-9, MBT2), breast cancer 
(SK-BR-3, MCF7), and other colon cancer (C26) cells [45,47]. However, their non-specificity 
presents a significant challenge in systemically administered applications for targeted 
delivery, as it requires precise control of CPP presentation only at the target site to prevent 
toxicity [48]. To overcome this problem, several approaches are being investigated to 
activate CPPs only at the target site. Stimulus-responsive materials may be used for this 
purpose, as they may provide triggered changes in material properties that allow spatially 
focused presentation of CPPs in response to intrinsic disease  characteristics (e.g. abundantly 
present extracellular matrix proteases) or locally applied extrinsic cues (e.g. apply heat or 
light at a specific location) [49].
As demonstrated in this study, TAT peptides can enhance cellular uptake when conjugated 
to lyophilisomes. In previous in vitro studies, lyophilisomes were loaded with anti-tumor 
drugs, e.g. doxorubicin and curcumin, which could eliminate tumor cells. Antibodies were 
conjugated to lyophilisomes resulting in specific binding to target cells [11,12]. To probe 
the possibility of using lyophilisomes for the treatment of cancer, active targeting with 
specific antibodies and enhanced cellular uptake with CPPs can be combined with the 
drug delivery properties of lyophilisomes, thereby creating a potential powerful tool for 
drug delivery.
 
CONCLUSION
In the present study, albumin-based lyophilisomes were functionalized with TAT peptides 
to obtain a drug delivery system with enhanced cellular uptake. Lyophilisomes modified 
with TAT peptides efficiently bound to HeLa, OVCAR-3, Caco-2 and SKOV-3 cells. Additional 
cellular uptake studies were performed to verify that TAT-conjugated lyophilisomes were 
internalized in HeLa cells after binding. TAT-conjugated lyophilisomes may present a novel 
delivery system to ensure faster and higher cellular uptake of anti-tumor drugs to cancer 
cells. 
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ABSTRACT
Lyophilisomes are a novel class of proteinaceous biodegradable nano/microparticle 
capsules developed for tumor drug delivery. The in vivo characteristics of lyophilisomes 
are unknown and, therefore, the time course of biodistribution of sized albumin-based 
lyophilisomes in CD1 mice after intravenous administration was studied. Lyophilisomes, 
prepared from Dylight680-labeled albumin, were sized using a sucrose gradient 
centrifugation methodology and four fractions with a mean size of approximately 200 
nm, 400 nm, 550 nm, and 650 nm were pooled for in/ex vivo localization, (immuno)
histochemistry and biochemical analysis. Lyophilisomes were rapidly taken out of the 
circulation by the liver and spleen. Immunohistochemistry revealed that lyophilisomes 
were taken up in the liver by F4/80 positive macrophages, and in the spleen by Sign-R1 
positive macrophages specifically located in the marginal zones. Lyophilisomes were 
most likely degraded by the liver and spleen and subsequently excreted via the urine, as 
high levels of degraded Dylight680-labeled albumin were detected in the urine. This was 
corroborated by electron microscopy of the spleen, which showed intact lyophilisomes in 
the marginal zone 5 and 30 min after injection, but not after 120 min. In conclusion, i.v. 
injected lyophilisomes are rapidly entrapped by liver and splenic macrophages, 
biodegraded, and excreted in the urine.
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INTRODUCTION
Nanoparticles and their potential application as drug delivery systems for pharmaceuti-
cals have been extensively studied [1,2]. Research has focused on drug delivery systems 
assembled from a range of materials including natural or synthetic lipid liposomes, metal 
particles, polymeric particles, amino acid-, sugar- and nucleotide-based micelles, and 
protein-based particles [3]. Sizes range from a few nanometers for dendrimers and 
micelles [4], up to hundreds of nanometers to micrometers for liposomes, polymersomes, 
and (protein-based) nanospheres [5–7]. Despite the abundant research on these drug 
delivery systems, only a few are currently clinically applied.
For cancer therapy, an effective strategy to deliver anti-tumor drugs may be intravenous 
injection of drug loaded nanoparticles. This methodology exploits the enhanced 
permeability and retention (EPR) effect that is associated with hyperpermeability of tumor 
vasculature and lack of lymphatic drainage [8–10]. Through normal endothelium, 
nanoparticles cannot extravasate as it is prevented by tight endothelial junctions (5 to 10 
nm) between endothelial cells [11]. However, the cut-off size for permeability in individual 
tumors is increased to 200 to 800 nm [12]. Due to this EPR effect, drug delivery particles 
(<800 nm) can extravasate from blood vessels to tumor tissue and accumulate, creating 
high local drug concentrations [13], with the potential to eliminate tumor cells more 
efficiently while reducing drug exposure to healthy cells. 
In a quest for stable and efficient carrier systems, we have developed a drug delivery 
system named ‘lyophilisomes’ [14]. Lyophilisomes are prepared by a freezing, annealing, 
and lyophilization process that results in stable nano to micrometer sized capsules. As 
base material, a wide range of water-soluble macromolecules can be used (e.g. albumin, 
elastin, and heparin), making it an adaptable carrier system towards multiple drug delivery 
applications. The system is flexible, allowing the incorporation of virtually any biomolecule 
in the wall and/or lumen. For instance, enzymes incorporated either in the capsule wall or 
the lumen remain biological active, partly due to mild preparation conditions [14]. 
Recently, we investigated lyophilisomes prepared from bovine serum albumin. Albumin 
as a core material for lyophilisomes harbors a number of beneficial characteristics for drug 
delivery systems, as it is biocompatible, biodegradable to yield only innocuous degradation 
products, non-toxic and non-immunogenic. Furthermore, albumin is easy to purify and 
widely available, making it a suitable candidate for nanoparticle preparation [15–19]. We 
have shown that albumin-based lyophilisomes can be efficiently loaded with doxorubicin 
or curcumin and are able to efficiently eliminate tumor cells in vitro [20]. In order to obtain 
a selective drug delivery system, albumin-based lyophilisomes have also been modified 
with antibodies resulting in specific targeting of the cell of interest and facilitating the 
uptake of lyophilisomes in vitro [21]. Moreover, lyophilisomes conjugated with cell 
penetrating peptides increased cellular association and internalization in tumor cells [22]. 
These data indicate that albumin-based lyophilisomes may be used as a targeting system 
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for the delivery of therapeutic agents. Although many parameters of lyophilisomes have 
been investigated in vitro, little is known about their characteristics in vivo. 
In this study, the biodistribution of lyophilisomes was investigated. Property sized 
lyophilisomes were administrated intravenously and the organ distribution and degradation 
characteristics were studied using bioluminescence, light/electron microscopy and bio - 
chemical assays.
MATERIALS & METHODS
Materials
Bovine serum albumin (BSA) was purchased from PAA Laboratories (Linz, Austria). 
Dylight680 (amine reactive) was purchased from Pierce (Rockford, IL, USE). Glutaraldehyde, 
formaldehyde and 4’,6-diamidino-2-phenylindole (DAPI) were obtained from Merck 
(Darmstadt, Germany). Rat anti-mouse F4/80 monoclonal antibody (MCA497RT, clone 
Cl:A3-1, lot 0212) and rat-anti mouse Sign-R1 (MCA2394Tl, clone Cl:ER-TR9, lot 0413) were 
obtained from AbD Serotec (Bio-Rad Laboratories, Hercules, CA, USA). Goat anti-rat IgG 
(H+L) Alexa fluor 488 conjugated antibody (A-11006, lot 52955A) and goat anti-rat IgM (µ 
chain) Alexa fluor 488 conjugated antibody (A-21212, lot 1252825) were purchased from 
Molecular Probes (Life Technologies, Grand Island, NY, USA).
Methods
Preparation of lyophilisomes
To image the lyophilisomes in vivo, Dylight680 (amine reactive) was conjugated to the free 
amine groups in albumin, applying the manufacturer’s protocol, and after dialysis in 0.01 
M acetic acid, labeled and non-labeled albumin were mixed in a 1:4 ratio. Albumin 
lyophilisomes were prepared as described [20]. Briefly, droplets of a solution of 0.25% (w/v) 
(labeled) BSA in 0.01 M acetic acid were frozen in liquid nitrogen (-196 °C) and then 
incubated at -10 to -20 °C for 3 h (annealing step), followed by lyophilization. This procedure 
results in hollow nano/micro spheres (‘‘lyophilisomes’’). Generally, we used 40 mL of a 
0.25% BSA solution, which corresponds to 100 mg albumin (2.5 mg/mL). One batch of 40 
mL was sufficient to perform the animal experiment. To stabilize lyophilisomes, they were 
vapor crosslinked with glutaraldehyde and formaldehyde. Subsequently, lyophilisomes 
were incubated in 1% (w/v) glycine (Scharlau, Barcelona, Spain) in phosphate buffered 
saline (PBS; pH 7.4) for 1 h under rotation to quench free aldehydes. Next, lyophilisomes 
were washed three times (17,000x g, 5 min, 4 °C) with 0.1% (v/v) Tween-20 (Sigma Aldrich, 
Steinheim, Germany) in phosphate buffered saline (PBS-T, pH 7.4). The final lyophilisome 
preparation was centrifuged three or four times at 60x g for 3 min to remove large 
lyophilisomes and sheet-like structures, until no pellet was observed. After this procedure, 
about 30% of the original weight of lyophilisomes remained. Lyophilisomes (1 mg/mL) 
were stored in PBS-T (pH 7.4). 
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Selecting appropriate sized lyophilisomes by density gradient centrifugation
In order to sort nanoparticles out of the lyophilisome population prepared as described 
above, centrifugation was used with a linear sucrose density gradient [23]. The linear 
sucrose density gradients were prepared in 14 mm diameter and 13.2 mL capacity ultra-
centrifuge tubes (ultra clear tubes, Beckman, Indianapolis, IN USA) by a gradient device 
that is composed of two chambers connected via a channel with a stopcock. To create a 
border for aggregated particles, 0.5 ml 60% (w/w) sucrose solution was placed on the 
bottom of the tube. Subsequently, the gradient was prepared by mixing 5.6 mL 10% (w/w) 
and 5.6 mL 40% (w/w) sucrose solution in a mixing chamber of which the 10% sucrose 
solution is loaded first. The final gradient volume was 11.7 mL. The prepared gradient was 
stored for one h at ambient temperature and loaded with the lyophilisome suspension 
(0.5 mL, 1.0 mg/ml). The tubes were placed in a swinging bucket rotor (SW 41 Ti rotor, 
Beckman) and centrifuged at 1,543x g in a Beckman Optima L-XP ultracentrifuge (Beckman) 
for 10 min. After centrifugation, fractions were collected using a peristaltic pump and a 
narrow tube, inserted from top to bottom in the centrifuge tube. For each fraction, 0.5 to 
1.0 mL of the solution was collected. Dynamic light scattering (DLS), qNano and analytical 
 ultracentrifugation (AUC) were used to analyze the mean size of the fractioned lyophilisomes. 
The lyophilisome concentration of each fraction was determined by optical density 
(λ = 280 nm) to investigate recovery. 
Particle characterization
Dynamic light scattering (DLS)
DLS was performed on a DynaPro Plate Reader Plus (Wyatt Technology Corporation, Santa 
Barbara, CA) equipped with a 60 mV linearly polarized gallium arsenide (GaAs) laser 
(λ = 832.5 nm), operating at an angle of 156°. DLS data were collected from lyophilisomes 
dispersed in PBS-T (pH 7.4). Data were analyzed using Dynamics software ver.6.10 by the 
method of cumulants [24]. 
qNano
The qNano (Izon, Science Ltd., Burnside, New Zealand) was used to measure particle size 
of lyophilisomes [20,25]. To ensure a continuous flow of particles, two different pore sizes 
were used. For unsorted lyophilisomes, a pore size of approximately 600 to 2,000 nm was 
used, while for sorted lyophilisomes a pore size of approximately 100 to 800 nm was used. 
Data were analyzed with Izon Control Suite 2.1 software. 
Analytical ultracentrifugation
Sedimentation velocity experiments were performed with a ProteomeLab XLI analytical 
ultracentrifuge (Beckman Coulter, Brea, CA), using conventional double-sector Epon 
centerpieces of 12 mm optical path length and a four-hole rotor (AN-60Ti). Rotor speed 
was set at 3,000 – 6,000 rpm, depending on the sample. The rotor was equilibrated in 
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advance for approximately 1 h at 20 °C in the centrifuge. Cells were filled with 420 μL 
sample solution and 440 μL solvent (0.5% BSA / 0.02% sodium azide in PBS). Sedimentation 
(s) profiles were obtained by interference optics at similar temperature. For analysis of the 
sedimentation velocity data, the distributions ls-g*(s) and c(s) with a Tikhonov–Phillips 
regularization procedure implemented into the Sedfit program were applied. Ls-g*(s) 
represents a least-square boundary analysis which describes sedimentation of 
non-diffusing species. c(s) analysis is based on the numerical resolution of the Lamm 
equation assuming an equal frictional ratio value for each s value [26]. 
In vivo biodistribution
The Ethical Committee on Animal Research of the Radboud University Nijmegen Medical 
Centre approved this study under protocol number RUDEC 2012-202. Twenty-one female 
CD-1 mice (Harlan Laboratories, Horst, the Netherlands, 8 to 12 weeks old) weighing 32 to 
40 g were caged in a controlled environment (23°C; 51% humidity, 12h light cycles). Food 
and water were available ad libitum. Mice were divided into seven groups of 3 mice per 
group. All groups received an intravenous injection of DyLight680-labeled albumin-based 
lyophilisomes in the tail vein at a concentration of 5.0 mg/kg body weight dissolved in PBS 
(1.0 mg/ml), except the control group (t=0); this group received a 5.0 mg/kg BSA in PBS 
injection. After 0, 5, 30 min, 2 h 5 h, 24 h and 96 h, mice were anesthetized with isoflurane/
oxygen, placed on their back into a light tight chamber and imaged for 10 min with a CCD 
camera in an in vivo imaging system (Xenogen IVIS Lumina II). DyLight680-labeled 
lyophilisomes were excited at 640 nm and emission in the range of 695 to 770 nm. To 
correct for autofluorescence, DyLight680-labeled lyophilisomes were excited at 605 nm 
and emission was recorded in the range of 695 to 770 nm. IVIS-images were quantified 
using the Living Image 3.0 software (Caliper Life Sciences, Hopkinton, MA, USA).
After imaging, mice were euthanized and urine was collected. In order to visualize 
lyophilisomes in individual organs, liver, spleen, lung, kidney, stomach, small intestine, 
colon, pancreas and skin tissue were dissected. These individual organs were imaged 
using similar settings as for the mice. For further examination, parts of liver, spleen, lung, 
and kidney tissue were collected and: 1) snap frozen in optimal cutting temperature 
compound (Tissue Tek, Sakura, Torrance, CA) for immunohistochemistry, 2) fixed in para-
formaldehyde and paraffin embedded for semi-quantification and 3) fixed in 2% (v/v) 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) for transmission electron microscopy.
Semi quantitative assessment using paraffin sections
Paraffin embedded tissue sections were cut at 5 µm, deparaffinized and rehydrated using 
standard procedures. Nuclei were stained with 1% (w/v) DAPI in 2% (w/v) BSA in PBS 
containing 0.05% (v/v) Tween-20 (BSA/PBS-T) for 15 min. For each mouse, a total of six 
fluorescent images were quantified per organ/time point out of two sections (40x 
magnification; 0.405 mm2 surface area). Sections were analyzed using a Zeiss LSM 510 laser 
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scanning confocal microscope (Carl Zeiss, Sliedrecht, the Netherlands). Dylight680-la-
beled lyophilisomes were excited at 633 nm and emission was collected between 650 and 
710 nm. DAPI and Alexa fluor 488 were excited at 405 nm and 488 nm with emission 
collected between 420 to 480 nm and 500 to 550 nm, respectively. Dylight680-labeled 
lyophilisomes were quantified in tissue sections with ImageJ 1.48o (National Institutes of 
Health, USA) with an automated script (see Supplemental information). A conservative 
threshold value of 100 was used to distinguish between background pixels and 
lyophilisomes, so that potential positive background pixels were excluded while the 
number of lyophilisomes was not underestimated.
Immunohistochemistry
Frozen liver tissues were sectioned (5 µm) and air dried. Sections were fixed in ice cold 
methanol for 10 min. Blocking was performed with BSA/PBS-T for 10 min. Samples were 
subsequently incubated with primary antibody F4/80 (1:500 in BSA/PBS-T), which 
recognizes a Kupffer cell marker, for 1 h, washed three times with PBS-T and incubated 
with secondary antibody goat anti-rat IgG Alexa fluor 488 conjugated (1:200 in BSA/PBS-T) 
for 45 min. 
Frozen spleen sections (5 µm) were air dried and blocked with 10% normal goat serum in 
BSA/PBS-T for 45 min and stained with primary antibody rat-anti mouse Sign-R1 (1:100), 
which recognizes a marker for marginal zone macrophages, in BSA/PBS-T for 1 h. 
Subsequently, sections were washed three times with PBS-T and blocked with 10% normal 
mouse serum BSA/PBS-T for 30 min. Secondary antibody Alexa fluor 488 conjugated goat 
anti-rat IgM (1:1,000 in BSA/PBS-T) was applied for 45 min.
All tissue sections were then washed three times with BSA/PBS-T and stained with 1% 
(w/v) DAPI in BSA/PBS-T for 15 min, washed three times with PBS-T and mounted with 
cover glasses in mowiol (Calbiochem, La Jolla, CA, USA). DAPI, Alexa fluor 488 and 
Dylight680 were visualized using settings as described in section ‘Semi quantitative 
assessment using paraffin sections’ using a Zeiss LSM 510 laser scanning confocal microscope. 
Contrast in all fluorescent channels was increased for visibility using Fiji imaging software 
(saturation set to 0.35).
Analysis of urine
After bioluminescence imaging, mice were euthanized and urine was collected. To 
investigate the presence of Dylight680-label in urine, Dylight680 fluorescent signal 
contained in 20 µl urine was determined in a 96-wells plate and analyzed by the IVIS 
apparatus. In addition, to investigate whether Dylight680-labeled lyophilisomes were 
degraded, sodium dodecyl sulphate polyacrylamide gel electrophoresis was performed. 
Urine samples (5 µl) were diluted (2x) in sample buffer and analyzed using a 4 to 20% 
precise protein gel (Thermo scientific, Rockford, IL, USA). As a reference, Dylight680-la-
beled lyophilisomes were digested with 2.5 U papain (Sigma Aldrich) in digestion buffer 
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(50 mM NaPO
4
, 2 mM cysteine, 2 mM EDTA, set at pH 6.5 with HCl) for 30 min at 65 °C. 
Fluorescent Dylight680 signal was detected with an Odyssey fluorescent gel scanner and 
analyzed using Odyssey software version 2.1 (Li-Cor Biosciences, Lincoln, Nebraska, USA). 
Subsequently gels were stained with 0.1% (w/v) Coomassie Brilliant Blue R-250 solution 
(MP Biomedicals, Santa Anna, CA) in 50% (v/v) methanol and 10% (v/v) acetic acid in water. 
Transmission electron microscopy
Glutaraldehyde-fixed samples were post-fixed with 1% (w/v) osmium tetroxide, dehydrated 
in an ascending series of ethanol, and embedded in Epon 812. Ultrathin sections (60 nm) 
were cut and picked up on Formvar-coated grids, post-stained with lead citrate and uranyl 
acetate, and examined in a JEOL 1010 transmission electron microscope (Tokyo, Japan).
Statistical Analysis
Data are presented as mean with standard deviation. Experimental data were analyzed 
using a one-way ANOVA Bonferroni multiple comparison post-hoc tests. All statistical 
analyses were performed in Graphpad Prism 5.03 (Graphpad, San Diego, CA, USA).
RESULTS
Characterization of lyophilisomes by dynamic light scattering,  
qNano and analytical ultracentrifugation
Analysis by qNano gave a mean size of 1,216±95 nm for unsorted lyophilisomes (please 
note that standard deviation represents deviation between means of three individual 
measurements). To probe the possibility of using lyophilisomes for tumor targeting, 
lyophilisomes were sorted by ultracentrifugation using a sucrose gradient. Particle size 
measurements were performed on four fractions (<1,000 nm) using DLS, qNano, and AUC 
(Table 1). Fraction 1, 2, 3, and 4 showed a mean size of approximately 200 nm, 400 nm, 550 
nm, and 650 nm, respectively (Fig. 1). The protein concentration of the fractions was 
determined by optical density (λ = 280 nm) to analyze recovery. The combination of the 
four fractions represented 16% of the total lyophilisome protein content. The number of 
lyophilisomes is likely higher than 16% of the initial number as small lyophilisomes contain 
less protein and thinner walls [14]. 
Biodistribution
To investigate the biodistribution of sorted lyophilisomes, Dylight680-labeled lyophilisomes 
were injected intravenously in mice. After multiple time intervals, the distribution of 
lyophilisomes was visualized and quantified using the Xenogen IVIS Lumina II imaging 
system. Bioluminescence imaging showed a rapid uptake of lyophilisomes in the upper 
abdominal area of the mice (Fig. 2). After 2 h, an additional fluorescent signal was visible in 
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the lower abdominal area. Both fluorescent signals were considerably diminished 24 h 
post injection (Fig. 2). Bioluminescence images of the individual organs are presented in 
figure 3a. Quantitative analysis of excised individual organs indicated that the majority of 
the lyophilisomes accumulated in the liver (Fig. 3b). However, when taking the weight of 
the organs into account, the spleen showed similar uptake of lyophilisomes per gram 
tissue compared to the liver (Fig. 3c).
Table 1   Lyophilisome recovery and mean size measurements of sorted lyophilisome 
fractions analyzed by dynamic light scattering (DLS), qNano and analytical 
ultracentrifugation (AUC). 
 
 
Lyophilisome protein DLS (nm) qNano (nm) AUC (nm)
recovery (%)
Fraction 1 3.0 260 ± 50 186 ± 19 195 ± 20
Fraction 2 3.8 445 ± 50 428 ± 40 360 ± 30
Fraction 3 4.3 610 ± 40 529 ± 57 530 ± 15
Fraction 4 5.1   690 ± 120 576 ± 75 685 ± 20
Figure 1  Size distributions of the four smallest lyophilisome fractions after a sucrose-gradient 
 ultracentrifugation procedure as analyzed by (a) analytical ultracentrifugation (AUC) and (b) dynamic 
light scattering (DLS). Lyophilisomes were prepared from 2.5 mg bovine serum albumin in 0.01 
M acetic acid using a freezing, annealing, and lyophilization regime. The average size distribution of 
the initial unfractioned lyophilisome preparation was 1,216±95 nm (qNano measurement).
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The number of lyophilisomes was also analyzed in paraffin sections of liver, spleen, kidney 
and lung. Figure 4 indicates that the liver and spleen entrapped the majority of the 
lyophilisomes per surface area. An interesting observation is that this analysis showed a 
higher uptake in the spleen than in the liver. Although both in vivo imaging and 
quantification in paraffin sections gave similar results in general, there are minor differences 
between liver and spleen entrapment. This is due to the specific entrapment in the 
marginal zone that was present in all images used for semi-quantification, which could 
induce an over-estimation. Compared to the liver and spleen, the number of lyophilisomes 
present in the lung was very small as only a few lyophilisomes were detected. In the 
kidney, only very few lyophilisomes were detected. Except for the kidney, in all tissue 
sections a rapid uptake of lyophilisomes was found with their number decreasing over 
time being almost gone 24 h post injection (Fig. 4). However, some fluorescent signal was 
detected in the excised kidney (Fig. 3c). As a result of the presence of fluorescent signal in 
the organ and absence of lyophilisomes in the kidney sections, it is expected that the 
fluorescent signal originates from degraded lyophilisomes. This hints to degradation of 
lyophilisomes and excretion by the kidneys (see section ‘Urine Analysis’).
Figure 2  Biodistribution of Dylight680-labeled albumin-based lyophilisomes after intravenous 
injection in mice. At multiple time points, the distribution of lyophilisomes was visualized using an 
in vivo imaging system. Lyophilisomes appeared predominantly in the upper abdominal area at 5 – 
30 min. In between (2 – 5 h after injection), lyophilisomes appeared also in the lower abdominal 
area. The signal decreased over time and is more or less absent at 24 h. Note that occasionally a 
fluorescent signal in the stomach was observed, due to autofluorescence of dietary chlorophyll. One 
mouse in the 96 h group died during the experiment of a non-experimentally related cause and was 
therefore not analyzed.
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Immunohistochemistry
Immunohistochemistry was performed to further evaluate the distribution of the 
lyophilisomes and identify the cells involved in internalization. Since most lyophilisomes 
were found in the liver and spleen, it was hypothesized that lyophilisomes were internalized 
by cells of the mononuclear phagocyte system. Therefore, frozen sections of the liver and 
spleen were stained with mouse macrophage marker F4/80. F4/80 staining showed that 
the majority of lyophilisomes in the liver was internalized by F4/80 positive cells (Fig. 5). 
Although lyophilisomes present in the red pulp of the spleen were found in F4/80 positive 
cells (results not shown), most lyophilisomes were internalized by cells present in the 
marginal zone. Macrophages of the spleen located in the rodent marginal zone are known 
to lack F4/80 expression [27]. Therefore, marginal zone macrophages were stained for 
Sign-R1 expression, a cell surface marker specific for marginal zone macrophages. Figure 6 
shows that the majority of lyophilisomes was internalized by SignR1 positive cells in the 
marginal zone.
Figure 3  Bioluminescence images of excised organs (liver, spleen, lung, kidney, stomach, small 
intestine, colon, pancreas and skin) after intravenous injection of Dylight680-labeled albumin-based 
lyophilisomes in mice (a).
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Figure 3  Continued. Quantitative analysis of fluorescent signal of lyophilisomes in liver, spleen, 
lung and kidney for total fluorescent signal of the organs (b) and fluorescent signal per mg wet 
weight tissue (c) after intravenous injection of Dylight680-labeled albumin-based lyophilisomes in 
mice. Absolutely, the highest uptake was observed in the liver, but per mg tissue a vast majority of 
lyophilisomes accumulated both in liver and spleen. In general, most fluorescence was measured 
after 5 – 30 min, after which the signal decreased over time. Fluorescence in stomach may be due to 
autofluorescence of dietary chlorophyll. Bars represent mean ± SD.
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Figure 4  Quantification of lyophilisomes present in liver, spleen, lung, and kidney at distinct time 
points after IV injection of lyophilisomes in mice by detection of Dylight680 label in paraffin sections. 
Left column: the number of lyophilisomes counted in tissue sections at several time points after 
injection. Lyophilisomes were predominantly found in liver and spleen and to minor extent in lung. 
From 2 h on, there was a slow decrease over time until hardly any lyophilisomes remained after 24 h. 
Bars represent mean ± SD. * p<0.05, ** p<0.01 and *** p<0.001. Right columns: Representative images used 
for quantification of lyophilisomes 5 min after injection. Dylight680-albumin lyophilisomes are 
depicted in green and nuclei were stained with DAPI (blue). Magnifications of the white squared 
boxes are depicted on the far right. Arrows indicate lyophilisomes. Scale bars represent 20 µm.
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Figure 5  Uptake of Dylight680-lableded lyophilisomes by liver cells at distinct time points after 
intravenous injection of Dylight680-labeled albumin-based lyophilisomes in mice by detection of 
Dylight680 label in frozen sections. Lyophilisomes (green) were specifically internalized by F4/80 
positive macrophages (red) in the liver. Nuclei were stained blue using DAPI. Magnifications of the 
white squared boxes are depicted in the figures below. Arrows indicate lyophilisomes. Scale bars 
represent 20 µm.
105
BIODISTRIBUTION OF LYOPHILISOMES
5
Figure 6  Uptake of Dylight680-lableded lyophilisomes by splenic cells at distinct time points 
after intravenous injection of Dylight680-labeled albumin-based lyophilisomes in mice by detection 
of Dylight680 label in frozen sections. Lyophilisomes (green) were especially taken up by Sign-R1 
splenic marginal zone macrophages (red) in the spleen. Nuclei were stained blue using DAPI. 
Magnifications of the white squared boxes are depicted in the figures below. Arrows indicate 
lyophilisomes. Scale bars represent 20 µm.
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Urine analysis
To investigate the fluorescent signal in the lower abdominal area, urine was collected after 
euthanizing the mice, and analyzed for the presence of Dylight680-label. Using the 
Xenogen IVIS Lumina II, a high fluorescent value was detected in urine 2 and 5 h post 
injection (Fig. 7a and b). To evaluate whether lyophilisomes were degraded and excreted 
in the urine, urine samples were analyzed on a protein gel in combination with fluorescence 
imaging (Fig. 7c and d). All urine samples, including controls, showed large bands around 
Figure 7  Excretion of degraded lyophilisomes via urine after intravenous injection of Dylight 680-
labeled albumin-based lyophilisomes in mice as analyzed by in vivo imaging (a and b) and SDS-PAGE 
(c and d) Dylight-680 signal in the urine was visualized (a) and quantified (b) using an in vivo imaging 
system. c-d) Gel electrophoresis analysis of urine with Coomassie brilliant blue staining (c) and 
Dylight680 detection (d). Normal non-digested lyophilisomes show a band around 70 kDa indicating 
albumin. Papain digested Dylight680 lyophilisomes do not show this band but do show fluorescence 
in the dye front of the gel, indicating degradation. In urine, major urinary proteins (±19 kDa) but no 
albumin/lyophilisomes (±70 kDa) were present. Presence of Dylight680 signal in dye front in urine 
samples taken 2 – 5 h after injection suggests lyophilisome degradation and excretion through urine. 
Bars represent mean ± SD. **2 and 5 h are significantly different from other time points (p<0.01).
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19 kDa corresponding to major urinary proteins [28,29]. Lyophilisomes (unlabeled) display 
a major band at about 70 kDa, representing albumin. After proteolytic digestion of 
lyophilisomes (Dylight680-labeled) using papain, no clear protein band was visible 
indicating major degradation (Fig. 7c). In this case, the fluorescent label was found in the 
dye front of the gel (Fig. 7d). A similar pattern was found in urine from mice 2 and 5 h after 
injection: no clear protein band visible at about 70 kDa but a clear fluorescent label in the 
gel’s dye front. This indicates that lyophilisomes are degraded and excreted in urine within 
300 min after injection.
Transmission electron microscopy
In order to visualize lyophilisomes within cells, transmission electron microscopy (TEM) 
was performed, focusing on the marginal zone areas in the spleen. Lyophilisomes that 
were largely intact could be identified primarily at time points 5 and 30 min after injection 
(Fig. 8). At 2 h, no lyophilisomes or lyophilisome-like structures could be detected, which 
suggests degradation (results not shown). Control samples also did not show any lyophi-
lisomes-like structures (results not shown). 
Figure 8  Transmission electron microscopical images of lyophilisomal structures in the spleen 
5 min (a) and 30 min (b) after intravenous injection of Dylight680-labeled albumin-based lyophilisomes 
in mice. Lyophilisomal structures were found in the marginal zone area in the spleen. Scale bar 
represents 2 µm.
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DISCUSSION 
Drug delivery systems require several properties to successfully deliver their cargo at the 
target site. Ideally, they are biocompatible, biodegradable, non-immunogenic and able to 
specifically deliver their cargo to target cells. Lyophilisomes are considered as new 
candidates for drug delivery. Recently, it has been shown that lyophilisomes can be loaded 
with anti-tumor drugs [20] and can specifically target MUC1 expressing tumor cells [21]. To 
ensure an effective treatment in vivo, long circulation times are preferred, whereas 
accumulation in non-targeted organs and premature degradation should be avoided. 
Particle size is considered as an important factor for circulation time since removal from 
circulation increases if the diameter of particles increases [30–32]. Previously, we sorted 
lyophilisomes using fluorescent activated cell sorting [21]. In this study, a straightforward 
sucrose-gradient centrifugation methodology was used to size lyophilisomes into 
fractions with mean diameters of about 200 nm, 400 nm, 550 nm and 650 nm. These four 
fractions were pooled to have sufficient lyophilisomes for the in vivo study. Since human 
albumin has a circulation time up to 19 days under physiological conditions [16,17], and is 
used to coat nanoparticles to improve circulation time [33], it was expected that our 
bovine albumin-based lyophilisomes would also exhibit a long circulation time. However, 
in vivo fluorescence imaging revealed that the majority of intravenously injected 
albumin-based lyophilisomes were rapidly removed from circulation by the liver and 
spleen from 5 min after injection. Semi-quantitative histology of paraffin tissue sections 
confirmed these findings. 
Rapid removal from the circulation is a common problem for drug delivery systems. 
The specific removal from circulation into liver and spleen can most likely be assigned to 
members of the mononuclear phagocyte system (MPS), also known as the reticulo-
endothelial system [16,34]. As the MPS is responsible for clearance of particles from the 
circulation, it was hypothesized that organs of this system clear lyophilisomes as well. 
Indeed, results indicate rapid removal from circulation by MPS members. Staining for 
F4/80 expression, a cell surface marker for macrophages cells [35], and Sign-R1, a cell 
surface marker specific for marginal zone macrophages, confirmed MPS based removal 
[35,36]. 
Our results are consistent with the kinetics and biodistribution of other non-modified 
drug delivery systems. Rapid removal of unmodified (nano)particles from circulation into 
liver and spleen has been observed for drug delivery systems prepared from various 
materials such as poly(lactic-co-glycolic) acid [37], poly D,L-lactide (PLA) [33], and egg 
phosphatidylcholine combined with cholesterol [38]. Albumin-based particles that were 
prepared by other methods than used in lyophilisome preparation were also scavenged 
by the liver and spleen. For instance, almost 60% of drug loaded BSA particles (mean 
diameter 600 nm) injected in rats were entrapped in the liver after 1 h [39]. In another drug 
loaded BSA particle system (mean size 826 nm), approximately 70% of the injected drug 
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from particles ended up in the liver of mice after 24 h, indicating phagocytic uptake [40]. 
Moreover, a biodistribution study in rats with three different sized HSA particles (180, 430 
and 1,800 nm) showed uptake in the liver of the 180 and 430 nm particles within 5 min, 
and uptake of larger particles mainly in the lung [41]. These studies are in contrast with the 
kinetics of smaller particles. Particles in the sub-100 nm range show prolonged circulation 
times and increased tumor accumulation [42], while smaller particles are directly excreted 
in the urine through the kidney’s fenestrae [43]. As larger particles are removed more 
rapidly from the circulation [30–32], the rapid removal of lyophilisomes and other albumin 
particles may be explained by their size. To verify this, lyophilisomes should be sized to a 
sub-100 nm size range to investigate whether size does indeed matter for this specific 
drug delivery system.
Depending on the biodegradability of the applied material, nanoparticles will either be 
degraded in MPS organs or accumulate and potentially induce toxic effects [44]. Lyophilisomes 
show superior degradation characteristics compared to less or non-degradable particles 
such as gold [45,46], titaniumoxide [47], silver [48] and silica nanoparticles [49], which 
accumulate in tissue organs for longer periods of time, specifically in liver in which they 
induced inflammation [45], apoptosis [45] and hepatic necrosis [49]. The remarkably rapid 
observed degradation and urinary excretion suggest that lyophilisomes most probably 
will not cause side-effects in these organs. Several lines of evidence indicate that 
lyophilisomes are degraded and do not accumulate in the body. We observed a significant 
decrease of lyophilisome signal after 5 h compared to 5 min after injection in combination 
with almost no signal after 24 h observed by full body in vivo imaging, substantiated by 
histological quantitative analysis and urine analysis. Polyak et al. observed a similar urine 
excretion with HSA particles [41]. Our TEM results indicate that lyophilisomes could be 
identified in the spleen up to 30 min, while lyophilisomes or lyophilisome-like fragments 
could not be found at the next time point (2 h), again suggesting rapid degradation and 
excretion. As a great part of the injected lyophilisomes was removed from the circulation 
by the liver, excretion through the hepato-biliarily route may be expected. However, in the 
current experimental set-up it was not possible to evaluate fluorescence in the hepato- 
biliary route due to autofluorescence of dietary chlorophyll.
When lyophilisomes are to be used as a drug delivery system, longer circulation times are 
required. Various methods have been developed to enable prolonged circulation times, 
such as PEGlyation [37,44], mimicking “self” by conjugating small peptide markers of self 
CD47 to the particle wall [50] or the use of smaller capsules [30]. Albumin Dylight680-ly-
ophilisomes as prepared in this study are rapidly removed from circulation and efficiently 
degraded. To increase circulation times, lyophilisomes could also be modified by either 
PEGlyating or a more biological method by using self peptides. To investigate the 
importance of lyophilisomal size and its effect on biodistribution, a study investigating the 
biodistribution of only the smallest sized fraction (with a mean size of about 200 nm in 
diameter) should be performed.
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Lyophilisomes may also be used in other settings that do not rely on long circulation 
times, but do take into account the biodegradability of albumin lyophilisomes. One 
example is the application of lyophilisomes in intraperitoneal chemotherapy [51,52] of 
malignant ascites, caused by ovarian, colorectal, pancreatic, or uterine cancers [53]. There 
is evidence that after intraperitoneal administration small particles (50 to 720 nm) are 
removed more rapidly than large particles (>4 µm) due to lymphatic drainage [54]. 
Originally developed lyophilisomes with sizes ranging from 200 nm to 10 µm [14] would 
very well fit this application. In addition, a previous study indicated that non-sized anti-
body-modified lyophilisomes were able to specifically target ovarian cancer cells under 
dynamic conditions making them suitable for this application [21]. This suggests that for 
future clinical IP administration, sizing of lyophilisomes and/or modification to prevent 
rapid removal from circulation may not even be necessary. 
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SUPPLEMENTAL INFORMATION
Automated script to count Dylight680 albumin labeled lyophilisomes in tissue sections 
using ImageJ 1.48o (National Institutes of Health, USA) with a conservative threshold value 
of 100.
// Get data set root folder from user
 sourcePath = getDirectory(“Choose a Directory”);
//create a goal path
goalPath = createGoalPath(sourcePath);
File.makeDirectory(goalPath);
//list the files
fileList = getFileList(sourcePath);
for (i=0; i<fileList.length; i++) {
if (endsWith(fileList[i], “/”)) {
imageList = getFileList(sourcePath + fileList[i]);
for (j = 0; j < imageList.length; j++) {
if (endsWith(imageList[j], “.lsm”)) {
imagePath = sourcePath + fileList[i] + imageList[j];
fileName = fileList[i] + imageList[j];
id = openImage(imagePath);
cOneFileName = fileName + “ - C=1”;
cTwoFileName = fileName + “ - C=3”;
cThreeFileName = fileName + “ - C=0”;
selectWindow(fileName + “ - C=1”);
setAutoThreshold(“Default dark”);
//run(“Threshold...”);
setThreshold(100, 255);
run(“Convert to Mask”);
run(“Make Binary”);
run(“Watershed”);
run(“Analyze Particles...”, “size=1-Infinity pixel circularity=0.00-1.00 show=Outlines clear summarize”);
// close the image
closeImage(id);
closeImage(id);
closeImage(id);
closeImage(id);
     } // end if
    } // end for
   } // end if
  } // end for
//create goal path
function createGoalPath(sourcePath) {
firstCharacter = 0;
finalCharacter = lengthOf(sourcePath) - 1;
cleanSourcePath = substring(sourcePath, firstCharacter, finalCharacter);
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goalPath = cleanSourcePath + “_enhanced”;
File.makeDirectory(goalPath)
return “” + goalPath + “/”; 
}
// Open an image
 function openImage(path) {
  run(“Bio-Formats Importer”, “open=[path] autoscale color_mode=Default split_channels view=Hyperstack stack_
order=XYCZT”);
    return getImageID();
 }
 // Close an image
 function closeImage(id) {
  close();
 }
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SUMMARY
Cancer is a leading cause of death and the global burden of cancer continues to increase 
rapidly because of aging and growth of the world population. For effective cancer therapy, 
it is necessary to improve our knowledge of cancer physiopathology, discover new 
anti-cancer drugs and develop novel biomedical technologies. Nanoparticulate drug 
delivery systems are currently explored to overcome critical challenges associated with 
classical administration forms. An overview concerning the use of nanoparticulate drug 
delivery systems to treat cancer and the most commonly used systems currently available 
are described in Chapter 1. 
The aim of this thesis was to modify lyophilisomes, a novel class of proteinaceous 
biodegradable nano/micro drug delivery capsules, in order to obtain albumin-based 
nanoparticles that can act as a drug delivery system to eliminate ovarian tumor cells. 
Chapter 2 describes protein-based lyophilisomes loaded with anti-tumor drugs. Among 
the available drug carrier systems, protein-based nanoparticles are particularly interesting 
as they hold certain advantages such as increased stability during storage, non-toxicity, 
biocompatibility, and biodegradability in vivo. Albumin-based lyophilisomes were prepared 
by freezing, annealing and Iyophilization. To probe the possibility to use lyophilisomes for 
tumor targeting, lyophilisomes were loaded with a high concentration of doxorubicin or 
curcumin. When tumor cells were exposed to doxorubicin or curcumin loaded albumin- 
based lyophilisomes, cell proliferation and viability of multiple tumor cell lines was strongly 
reduced. This work provided the basis that lyophilisomes may be suitable as a drug 
delivery system in vitro and further development is justified.
As a further development of lyophilisomes as a drug delivery system, chapter 3 describes 
the specific targeting of antibody-conjugated lyophilisomes to tumor cells. Lyophilisomes 
modified with hKC4-antibodies against mucin-1 (MUC1) were shown to specifically target 
ovarian tumor cells overexpressing the MUC1 antigen. To establish the specificity of 
hKC4-modified lyophilisomes, MUC1 positive and negative tumor cells were cultured in one 
culture flask. This experiment showed that hKC4-antibody conjugated lyophilisomes 
specifically targeted to MUC1 overexpressing ovarian tumor cells. In continuation of 
chapter 3 to further modify lyophilisomes, chapter 4 describes the effect of cell penetrating 
peptides (CPPs) conjugated to lyophilisomes. CPPs including the TAT peptide can be used for 
intracellular delivery of a broad variety of cargos including nanoparticulate pharmaceutical 
carriers. Lyophilisomes modified with a TAT-peptide demonstrated that intracellular uptake 
was facilitated in a time-dependent manner. In addition, when using lyophilisomes for tumor 
targeting, lyophilisomal size is also an important parameter. Chapter 4 also focused on 
fractionation of the lyophilisome preparation (size up to 2.8 µm) to obtain nanosized 
lyophilisomes with a more monodisperse capsule population. Using FACS, lyophilisomes 
could be sorted with a particle diameter smaller than 1 µm.
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Chapter 5 describes the biodistribution of nano-sized lyophilisomes. Using a sucrose 
gradient centrifugation, lyophilisomes could be size-selected more precisely (to the nm 
range) and resulted in a higher yield compared to FACS as described in chapter 4. The 
biodistribution in mice demonstrated that lyophilisomes did not induce acute toxic 
effects and were released through the urine after degradation. An effective drug delivery 
system should circulate in the blood stream long enough to reach the tumor site. 
Lyophilisomes were rapidly removed from the circulation by the mononuclear phagocyte 
system (predominantly liver and spleen), postulating that lyophilisomes should be modified 
in size or outer surface to prevent early removal from the circulation.
In conclusion, this thesis describes the potential of albumin-based lyophilisomes as a drug 
delivery system for anti-tumor drugs. In order to use lyophilisomes in vivo, more research 
is needed including modifications to increase circulation times.
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SAMENVATTING
Kanker is inmiddels wereldwijd de belangrijkste doodsoorzaak en zal in de toekomst 
alleen maar toenemen als gevolg van de veroudering en groei van de wereldbevolking. 
Voor het ontwikkelen van effectieve kankertherapieën is het noodzakelijk om onze kennis 
van de fysiopathologie van tumorweefel te verbeteren, nieuwe cytostatica te ontdekken 
en innovatieve biomedische technologieën te ontwikkelen. Tegenwoordig wordt er veel 
onderzoek verricht naar nanodeeltjes die als drug delivery systeem (medicijnafgifte-
systeem) kunnen dienen om de beperkingen die gepaard gaan met de klassieke kanker-
therapie te overwinnen. Hoofdstuk 1 geeft een overzicht hoe nanodeeltjes functioneren 
als drug delivery systeem om kanker te behandelen en beschrijft de meest gebruikte 
nanodeeltjes die kunnen fungeren als drug delivery systemen.
Het doel van dit proefschrift was het modificeren van lyophilisomen, een nieuwe categorie 
op eiwit gebaseerde biologisch afbreekbare nano/micro drug delivery capsules, om 
nanocapsules van albumine te verkrijgen die kunnen dienen als een drug delivery systeem 
om ovariumtumorcellen te elimineren.
Hoofdstuk 2 beschrijft lyophilisomen gemaakt van albumine en opgeladen met 
anti-tumor medicijnen. Nanodeeltjes gemaakt van eiwitten zijn bijzonder interessant in 
vergelijking met de huidige beschikbare carriersystemen, omdat deze deeltjes meerdere 
voordelen hebben zoals verbeterde stabiliteit tijdens opslag. Daarnaast zijn ze niet toxisch, 
biocompatibel en in vivo biologisch afbreekbaar. Lyophilisomen worden gemaakt door 
middel van drie verschillende processen: invriezen, opwarmen tot -10 °C en vriesdrogen. 
Om te onderzoeken of lyophilisomen gebruikt kunnen worden als kankertherapie, zijn de 
capsules opgeladen met een hoge concentratie doxorubicine en curcumine. Tumorcellen 
die werden blootgesteld aan albumine-lyophilisomen opgeladen met doxorubicine of 
curcumine, lieten een sterke daling in celproliferatie en viabiliteit zien bij verschillende 
tumorcellijnen. Bovenstaand werk vormt de basis voor de toepassing van lyophilisomen 
als drug delivery systeem in vitro en rechtvaardigt verdere ontwikkeling van dit systeem. 
Om lyophilisomen verder te ontwikkelen als drug delivery systeem, beschrijft hoofdstuk 3 
lyophilisomen waaraan antilichamen zijn geconjugeerd om specifiek tumorcellen te 
targeten. Lyophilisomen gemodificeerd met hKC4 antilichamen gericht tegen mucin1 
(MUC1) binden specifiek aan tumorcellen die het MUC1 antigen tot overexpressie brengen. 
Om de specificiteit van hKC4 gemodificeerde lyophilisomen vast te stellen is een experiment 
ontwikkeld waarbij twee celtypen -een MUC1 positieve en negatieve cellijn- werden 
gecombineerd in één celkweek. Dit experiment toonde aan dat hKC4-geconjugeerde 
lyophilisomen specifiek binden aan de tumorcellen die MUC1 tot overexpressie brengen. 
Als vervolg op hoofdstuk 3, om de lyophilisomen verder te modificeren, beschrijft 
hoofdstuk 4 het effect van cel-penetrerende peptiden (CPPs) geconjugeerd aan 
lyophilisomen. CPPs, waaronder het TAT peptide, kunnen worden gebruikt voor de 
 intracellulaire afgifte van verschillende ladingen inclusief nanodeeltjes. Lyophilisomen 
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gemodificeerd met het TAT peptide werden sneller opgenomen door de tumorcel in 
vergelijking tot lyophilisomen zonder TAT peptide in een tijdsafhankelijk proces. Naast de 
opname van een nanodeeltje is ook de grootte van het deeltje belangrijk. Dit hoofdstuk 
benadrukt daarom ook het fractioneren van lyophilisomen (diameter tot 2.8 µm) en leidt 
tot een populatie lyophilisomen met minder variatie in diameter. Met behulp van FACS 
konden lyophilisomen worden gesorteerd tot een diameter kleiner dan 1 µm. 
Hoofdstuk 5 beschrijft de biodistributie van gesorteerde nano-lyophilisomen. Met 
behulp van sucrosegradiënt-centrifugatie kunnen lyophilisomen nauwkeuriger worden 
gesorteerd (in de nanometer range). Daarnaast resulteerde deze methode ook in een 
hogere opbrengst in vergelijking met FACS zoals beschreven in hoofdstuk 4. De 
biodistributie in muizen toonde aan dat lyophilisomen geen acute toxische effecten 
induceerden en werden na afbraak uitgescheiden via de urine. Effectieve drug delivery 
systemen moeten lang genoeg in de bloedstroom circuleren om via “lekke bloedvaten” 
de tumor te bereiken. Lyophilisomen worden snel uit de circulatie verwijderd door het 
mononucleaire fagocytensysteem (voornamelijk lever en milt). Met de vergaarde kennis is 
duidelijk geworden dat lyophilisomen voor toekomstig onderzoek verder moeten worden 
gesorteerd (kleinere diameter) of aan het oppervlak moeten worden aangepast om 
vroegtijdige verwijdering uit de circulatie te voorkomen.
Concluderend beschrijft dit proefschrift de potentie van albumine-lyophilisomen als een 
drug delivery systeem voor anti-tumor medicijnen. Om lyophilisomen in de toekomst 
in vivo te kunnen gebruiken is verder onderzoek nodig waaronder aanpassingen om de 
circulatietijd van lyophilisomen te verlengen.
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FUTURE DIRECTIONS
Design and synthesis of efficient drug delivery systems are of vital importance for medicine 
and healthcare. Materials innovation and nanotechnology continues to be an expanding 
field, and in this thesis we showed the potential of albumin-based lyophilisomes for drug 
delivery. We developed albumin-based lyophilisomes that can be loaded with anti-tumor 
drugs and functionalized with antibodies and cell penetrating peptides (CPPs) in order to 
be used as a comprehensive drug delivery system.
The ideal nanoparticulate drug delivery systems should consist of nanoparticles that can 
specifically deliver a high quantity of anti-tumor drug into the tumor cell in order to 
eliminate the cancer. It has already been demonstrated that multiple drug delivery 
systems can be loaded with various anti-cancer drugs [1]. However, when drug delivery 
systems are administered intravenously, they need to be able to reach the tumor site. This 
generally occurs due to the enhanced permeability effect. Theoretically, one would prefer 
to only eliminate the tumor cells and preserve healthy tissue. Antibodies may improve the 
specificity substantially, as demonstrated in Chapter 3. They may specifically target the 
nanoparticle to the tumor cells when extravasated out of the circulation. In addition, CPPs 
are a powerful tool that allow penetration of the cellular membrane and, when coupled 
to nanocapsules, facilitate their cellular uptake (Chapter 4). For future research, a key 
investigation would be to combine CPPs with tumor-specific antibodies [2,3]. Due to their 
larger size, antibodies may cover the CPPs preventing intracellular uptake of the capsules 
by healthy tissue and allowing CPPs to only function at the tumor site after binding. In 
combination with cytotoxic agents, antibodies will provide specificity, while CPPs will 
ensure rapid internalization of the lyophilisome, as not all antibodies trigger internaliza-
tion, thereby reducing the negative side effects of cytostatic agents on healthy cells, and 
potentially even resulting in accelerated tumor degradation. Harnessing the power of 
CPPs for tumor targeted delivery has been pursued by a variety of mechanisms. Stimu-
lus-responsive materials may be applied for this purpose, as they may provide triggered 
changes in material properties that allow spatially focused presentation of CPPs in 
response to intrinsic disease characteristics (e.g. abundantly present extracellular matrix 
proteases) or locally applied extrinsic cues (e.g. application of heat or light at a specific 
location) [4,5]. In in vitro experiments, it has been shown that lyophilisomes modified with 
antibodies and CPPs, result in specific targeting and enhanced cellular uptake. In addition, 
lyophilisomes could be loaded with anti-tumor drugs resulting in strongly reduced cell 
viability in vitro. Further studies on the combination of these modifications are needed to 
provide evidence-based data to support this approach to fight cancer. 
Besides in vitro research, more in vivo investigation is required. Before drug delivery systems 
reach the target site, they need to travel through the vascular bed. Particle size has a 
fundamental effect on the biodistribution [6]. In this thesis, lyophilisomes were sized- 
selected using Fluorescent Activated Cell Sorting (FACS) and sucrose-gradient centrifugation. 
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Although these methodologies resulted in a more monodisperse particle population 
within the nanometer range, more research is needed to develop a method to increase 
the amount of nano-sized lyophilisomes (±200 nm). These size-selected lyophilisomes are 
more suitable to employ the enhanced permeability effect in tumors. In addition, a better 
understanding of the behavior of lyophilisomes in vivo may lead to the identification of 
important parameters that can be adjusted to increase circulating times. Various methods 
have been developed to enable prolonged circulation times, such as PEGlyation [7,8], 
albumin coating [9], the use of smaller capsules [6]. Recently Rodriguez et al. demonstrated 
a minimal “self” peptide that inhibited phagocytic clearance and enhanced delivery of 
nanoparticles [10]. Lyophilisomes could be modified to achieve longer circulation times by 
one of these methodologies. However, besides intravenous administration to target 
tumor tissue, cancers such as ovarian, colorectal, pancreatic, or uterine cancer can also 
profit from intraperitoneal (IP) administration of chemotherapeutics [11]. IP chemo-
therapeutics allow higher dosages and more frequent administration of drugs, and it 
appears to be more effective in eliminating cancer cells in the peritoneal cavity [12,13]. 
However, IP chemotherapy has also led to significantly higher toxic side effects, since both 
tumor cells and healthy cells in the peritoneal cavity are exposed to high concentrations 
of the chemo therapeutic [14,15]. Nano/microparticulate drug delivery systems can 
potentially improve current IP treatment of ovarian cancer, especially when delivering 
chemo therapeutics with targeting moieties through cancer cell surface markers [16,17]. 
There is evidence that intraperitoneally, small particles (50 to 720 nm) are removed more 
rapidly compared to larger (>4 µm) particles due to lymphatic drainage [18]. As the 
originally developed unsized lyophilisomes showed a size ranging from 200 nm to 10 µm 
[19], they may be suitable for IP applications. As demonstrated in this thesis, antibody- 
modified lyophilisomes, which were not sized, were able to specifically target cancer cells 
under dynamic conditions, making them suitable for this application. Future research into 
IP applications/therapies should therefore be pursued. For clinical IP applications, sizing of 
lyophilisomes and modification to prevent rapid removal from circulation may not even 
be necessary. 
For biomedical applications, it would be advantageous if capsules could be prepared 
from a wide repertoire of natural (proteinaceous) macromolecules. As Daamen et al. 
demonstrated, lyophilisomes could be prepared from a variety of macromolecules, 
including serum albumin (67 kDa), type I collagen (280 kDa), and heparin (15 kDa), a highly 
negatively charged polysaccharide [19]. This indicates the versatility of lyophilisomes and 
the ability to address the variety of medical demands. One may think of lyophilisomes that 
are prepared from specific macromolecules that will be degraded at the site of action, 
were it subsequently releases the drug. Therefore, future research should also focus on the 
feasibility to prepare lyophilisomes from a variety of macromolecules and obtain more 
knowledge of those carriers with respect to drug delivery.
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When these issues can be addressed, lyophilisomes may result in an innovative (albumin)- 
based drug delivery system that will have a significant contribution to treat multiple 
cancer types.
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TOEKOMSTVISIE
Het ontwerp en de ontwikkeling van efficiënte drug delivery systemen (medicijn afgifte-
systemen) is van vitaal belang voor de geneeskunde en de gezondheidszorg. Het onder-
zoeksgebied waar materiaalinnovatie en nanotechnologie elkaar raken, ontwikkelt zich 
nog steeds. Dit proefschrift laat de potentie van albumine-lyophilisomen zien in relatie 
tot gerichte drug delivery. De ontwikkelde albumine-lyophilisomen kunnen worden 
opgeladen met geneesmiddelen tegen kanker en worden gefunctionaliseerd met anti - 
lichamen en cel-penetrerende peptiden (CPPs), wat resulteert in een uitgebreid drug 
delivery systeem.
Het optimale drug delivery systeem moet bestaan uit nanodeeltjes die specifiek een 
grote hoeveelheid aan anti-tumor geneesmiddel in een tumorcel kunnen afleveren om 
de kanker te elimeneren. In eerder onderzoek is aangetoond dat meerdere drug delivery 
systemen kunnen worden opgeladen met verschillende anti-tumor medicijnen (1). 
Wanneer drug delivery systemen intraveneus worden toegediend, moeten ze in staat zijn 
het tumorweefsel te bereiken. Dit gebeurt doorgaans door middel van het verhoogde 
permeabiliteitseffect. Theoretisch zou men graag alleen de tumorcellen elimineren en het 
gezonde weefsel behouden. Antilichamen kunnen de specificiteit van geneesmiddelen 
tegen tumoren aanzienlijk verbeteren, zoals wordt aangetoond in Hoofdstuk 3. Anti- 
lichamen kunnen het nanodeeltje specifiek naar de tumorcellen leiden na extravasatie uit 
het bloed. Daarnaast is er een actieve interesse in CPPs die gemakkelijk celmembranen 
kunnen passeren zonder de hulp van celmembraanreceptoren. Als CPPs aan nanocapsules 
worden gekoppeld, zorgt dit voor een versnelde opname van de capsule (Hoofdstuk 4). 
Een belangrijk experiment voor toekomstig onderzoek is het combineren van CPPs met 
tumor-specifieke antilichamen (2, 3). Antilichamen zijn door hun grootte mogelijk in staat 
om CPPs te beschermen waardoor de capsules niet worden opgenomen door gezond 
weefsel en CPPs pas functioneel worden na binding op de plek van de tumor. In dit geval 
zorgen de antilichamen voor specificiteit en de CPPs voor versnelde opname aangezien 
niet alle antilichamen aanzetten tot internalisatie. Gecombineerd met cytostatica zullen 
de negatieve bijwerkingen op gezond weefsel afnemen, wat potentieel zelfs kan resulteren 
in een versnelde tumorafbraak. 
Om CPPs te gebruiken voor tumorspecifieke drug delivery en slechts te activeren op de 
plaats van bestemming zijn verscheidene mechanismen nagestreefd, gebaseerd op 
 stimulus-reagerende materialen. Deze materialen kunnen specifieke triggers initiëren waardoor 
de eigenschap van het materiaal verandert en de presentatie van CPPs mogelijk maakt. 
Bijvoorbeeld in reactie op intrinsieke kenmerken van de ziekte zoals de aanwezigheid van 
een overvloed aan extracellulaire matrixeiwitten of lokaal toegepaste extrinsieke signalen 
zoals het toepassen van warmte of licht op een bepaalde locatie (4, 5). In vitro experimenten 
toonden aan dat gemodificeerde lyophilisomen met antilichamen en CPPs zorgen voor 
specifieke targeting en versnelde opname. Bovendien kunnen lyophilisomen worden 
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opgeladen met anti-tumor geneesmiddelen wat leidt tot een sterk verminderde celviabiliteit 
in vitro. Verder onderzoek naar de combinatie van antilichamen en CPPs is essentieel om 
deze strategie te ondersteunen met meer data.
Naast in vitro onderzoek is ook meer in vivo onderzoek noodzakelijk. Voordat drug delivery 
systemen hun doel (tumorcellen) in vivo bereiken circuleren ze door het bloedvatenstelsel. 
De diameter van het drug delivery systeem heeft een fundamentele invloed op de 
biodistributie (6). In dit proefschrift zijn lyophilisomen geselecteerd op basis van grootte 
door middel van Fluorescent Activated Cell Sorting (FACS) en sucrose-gradiënt 
centrifugatie. Deze methodes hebben geleid tot een populatie lyophilisomen met minder 
variatie in diameter (nanometer range). Echter, meer onderzoek is nodig om een methode 
te ontwikkelen waarbij grotere hoeveelheden lyophilisomen van ±200 nm kunnen 
worden verkregen, omdat nanodeeltjes van deze grootte beter geschikt zijn om gebruik 
te maken van het verhoogde permeabiliteitseffect in tumoren. Bovendien zal meer in vivo 
kennis van lyophilisomen leiden tot een beter inzicht in het gedrag van lyophilisomen in 
bloed, waaruit vervolgens belangrijke parameters kunnen worden geïdentificeerd om de 
circulatietijden te vergroten. Verschillende methodes zijn ontwikkeld om nanodeeltjes 
langdurig in de bloedbaan te laten circuleren, zoals PEGylatie (7, 8), albumine coating (9), 
en het gebruik van kleinere capsules (6). Recentelijk is door Rodriguez et al. een ”eigen” 
peptide aangetoond die de fagocyterende klaring remt en anderzijds zorgt voor een 
verhoogd aantal nanodeeltjes die de tumor bereikt (10). Lyophilisomen kunnen door 
bovenstaande methodes worden gemodificeerd om een langere circulatietijd te bereiken. 
Echter, naast intraveneuze toediening om tumors te bereiken kunnen andere soorten 
kanker zoals ovarium-, darm-, alvleesklier-, of baarmoederkanker ook baat hebben bij 
intre peritoneale (IP) toediening van anti-tumor medicijnen (11). 
IP anti-tumor medicijnen kunnen in hogere doseringen en frequenter worden toegediend en 
lijken effectiever in het elimineren van tumorcellen in de buikholte (12, 13). Echter, IP 
chemotherapie heeft ook geleid tot significant meer toxische bijwerkingen doordat zowel 
tumorcellen als gezonde cellen in de buikholte worden blootgesteld aan hoge concentraties 
van de anti-tumor medicijnen (14, 15). Drug delivery systemen in de nano/micrometer range 
kunnen mogelijk de huidige IP behandeling van ovarium kanker verbeteren door anti-tumor 
medicijnen specifiek te richten tegen markers op het oppervlak van de tumorcel (16, 17). 
Literatuur bewijst dat kleine deeltjes (50 tot 720 nm) sneller worden verwijderd in de 
buikholte door lymfatische drainage in vergelijking met grotere (>4 µm) deeltjes (18). De 
oorspronkelijk ontwikkelde (niet gesorteerde) lyophilisomen hebben een diameter variërend 
van 200 nm tot 10 µm (19). Dit proefschrift toonde aan dat antilichaam-gemodificeerde 
lyophilisomen (niet gesorteerd) in staat zijn om tumorcellen specifiek te targeten onder 
dynamische condities. Dit maakt lyophilisomen eventueel geschikt voor IP-toepassingen. 
Daarom moet toekomstig onderzoek naar IP toepassingen/therapieën worden voortgezet. 
Voor klinische IP toepassingen is het mogelijk niet eens nodig om lyophilisomen te sorteren 
en te modificeren om snelle verwijdering uit de circulatie te voorkomen.
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Voor biomedische toepassingen zou het een voordeel zijn als capsules geproduceerd 
kunnen worden uit een brede selectie van natuurlijke (eiwithoudende) macromoleculen. 
Zoals aangetoond door Daamen et al. kunnen lyophilisomen gemaakt worden van 
verschillende macromoleculen, zoals serum albumine (67 kDa), type 1 collageen (280 kDa) 
en heparine (15 kDa), een sterk negatief geladen polysaccharide (19). Dit geeft de 
veelzijdigheid aan van lyophilisomen en het vermogen om aan de vraag naar verschillende 
medische toepassingen te voldoen. Lyophilisomen kunnen bijvoorbeeld gemaakt worden 
van specifieke macromoleculen, die worden gedegradeerd op de plaats van bestemming 
waar vervolgens het medicijn vrij komt. Daarom zal toekomstig onderzoek zich ook 
moeten richten op de productie van lyophilisomen van verschillende macro moleculen 
om meer kennis te verkrijgen van deze carriers in relatie tot drug delivery.
Als deze problemen worden aangepakt kunnen lyophilisomen tot een innovatief drug 
delivery systeem leiden dat een significante bijdrage kan leveren aan de behandeling van 
meerdere soorten kanker.
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